1
|
Lin M, Zhang Y, Lv D, Xu N, Yang X, Liu X, Yan C, Wu M, Kai J, Hu S, Zhao Q. The impact of CYP3A5*3 on oral quetiapine: A population pharmacokinetic model in Chinese bipolar disorder patients. J Affect Disord 2024; 351:309-313. [PMID: 38262522 DOI: 10.1016/j.jad.2024.01.170] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/01/2023] [Revised: 01/15/2024] [Accepted: 01/17/2024] [Indexed: 01/25/2024]
Abstract
BACKGROUND There is great interindividual difference in the plasma concentration of quetiapine, and optimizing quetiapine therapy to achieve a balance between efficacy and safety is still a challenge. In our study, a population pharmacokinetic (PPK) model considering genetic information was developed with the expectation of comprehensively explaining this observation in Chinese patients with bipolar disorder. METHODS Patients who were dispensed quetiapine and underwent the therapeutic drug monitoring (TDM) were included. The genotypes of CYP3A5*3, CYP2D6*10, and ABCB1 C3435T/G2677T were analyzed. Finally, a multivariable linear regression model was applied to describe the PPK of quetiapine considering the covariates weight, height and genotype information. RESULTS A total of 175 TDM points from 107 patients were adopted for PPK model development. Resultantly, the CL/F of quetiapine in CYP3A5 expressers was 81.1 CL/h, whereas it was 43.6 CL/h in CYP3A5 nonexpressers. The interindividual variability in CL/F was 47.7 %. However, neither the ABCB1 nor CYP2D6 genotype was significantly associated with the predictor of quetiapine clearance in our study. LIMITATIONS Only trough concentrations were collected, and the span between different points was relatively wide, impeding the application of the typical nonlinear compartment model for PPK analysis. In addition, this was a single-center study which limited the sample of wild-type CYP3A5 carriers. CONCLUSIONS The currently established PPK model of quetiapine considering the contribution of the CYP3A5 genotype could efficiently predict the population and individual pharmacokinetic parameters of Chinese bipolar disorder patients, which could better guide the personalized therapy with quetiapine, thus to achieve the best clinical response.
Collapse
Affiliation(s)
- Meihua Lin
- Department of Clinical Pharmacy, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China; Zhejiang Provincial Key Laboratory for Drug Evaluation and Clinical Research, Hangzhou 310003, China; Zhejiang Provincial Key Laboratory of Traditional Chinese Medicine for Clinical Evaluation and Translational Research, Hangzhou 310003, China
| | - Yu Zhang
- Department of Clinical Pharmacy, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China
| | - Duo Lv
- Department of Clinical Pharmacy, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China; Zhejiang Provincial Key Laboratory for Drug Evaluation and Clinical Research, Hangzhou 310003, China
| | - Nana Xu
- Department of Clinical Pharmacy, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China; Zhejiang Provincial Key Laboratory for Drug Evaluation and Clinical Research, Hangzhou 310003, China
| | - Xi Yang
- Department of Clinical Pharmacy, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China; Zhejiang Provincial Key Laboratory for Drug Evaluation and Clinical Research, Hangzhou 310003, China
| | - Xueling Liu
- Department of Clinical Pharmacy, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China; Zhejiang Provincial Key Laboratory for Drug Evaluation and Clinical Research, Hangzhou 310003, China
| | - Caixia Yan
- Department of Clinical Pharmacy, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China; Zhejiang Provincial Key Laboratory for Drug Evaluation and Clinical Research, Hangzhou 310003, China
| | - Meijia Wu
- Department of Clinical Pharmacy, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China; Zhejiang Provincial Key Laboratory for Drug Evaluation and Clinical Research, Hangzhou 310003, China
| | - Jiejing Kai
- Department of Clinical Pharmacy, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China; Zhejiang Provincial Key Laboratory for Drug Evaluation and Clinical Research, Hangzhou 310003, China
| | - Shaohua Hu
- Department of Psychiatry, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China; The Key Laboratory of Mental Disorder's Management of Zhejiang Province, Zhejiang Engineering Center for Mathematical Mental Health, Hangzhou 310003, China; Brain Research Institute of Zhejiang University, Hangzhou 310003, China.
| | - Qingwei Zhao
- Department of Clinical Pharmacy, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China; Zhejiang Provincial Key Laboratory for Drug Evaluation and Clinical Research, Hangzhou 310003, China; Zhejiang Provincial Key Laboratory of Traditional Chinese Medicine for Clinical Evaluation and Translational Research, Hangzhou 310003, China.
| |
Collapse
|
2
|
Yin Z, Zhao Q, Lv X, Zhang X, Wu Y. Circular RNA ath-circ032768, a competing endogenous RNA, response the drought stress by targeting miR472-RPS5 module. Plant Biol (Stuttg) 2024. [PMID: 38588338 DOI: 10.1111/plb.13645] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/21/2023] [Accepted: 02/21/2024] [Indexed: 04/10/2024]
Abstract
CircRNAs (circular RNAs) reduce the abundance of miRNAs through ceRNA (competing endogenous RNA), to regulate many physiological processes and stress responses in plants. However, the role of circRNA in drought stress is poorly understood. Through ring identification and sequencing verification of ath-circ032768, bioinformatics analysis predicted the interaction of ath-circ032768-miR472-RPS5, and further obtained transgenic plants overexpressing ath-circ032768 and silencing STTM-miR472. The change in drought stress was analysed using biochemical and molecular biological methods. Sequencing and biological analysis confirmed that ath-circ032768, miR472 and RPS5 were responsive to drought stress, and changes in gene expression were consistent with the prediction of ceRNA. The silencing vectors ath-circ032768 and STTM-miR472 were constructed using molecular biology techniques, and stable transgenic plants with drought tolerance obtained. Further physiological and biochemical studies showed that ath-circ032768 could bind to miR472, and that miR472 could bind to the RPS5 gene, resulting in decreased expression of RPS5. Hence, ath-circ032768 can competitively inhibit degradation of RPS5 by miR472 through ceRNA. This process is accompanied by increased expression of DREB2A, RD29A and RD29B genes. Through the ath-circ032768-miR472-RPS5 pathway, the RPS5 stress resistance protein interacts with DREB2A protein to enhance expression of downstream drought resistance genes, RD29A and RD29B, and participate in the regulation mechanism of plant drought resistance, thereby improving drought tolerance of plants.
Collapse
Affiliation(s)
- Z Yin
- College of Life Sciences, Northwest A&F University, Yangling, Shaan Xi, China
| | - Q Zhao
- College of Life Sciences, Northwest A&F University, Yangling, Shaan Xi, China
| | - X Lv
- College of Life Sciences, Northwest A&F University, Yangling, Shaan Xi, China
| | - X Zhang
- College of Life Sciences, Northwest A&F University, Yangling, Shaan Xi, China
| | - Y Wu
- College of Life Sciences, Northwest A&F University, Yangling, Shaan Xi, China
| |
Collapse
|
3
|
Wu M, Wang Q, Li X, Yu S, Zhao F, Wu X, Fan L, Liu X, Zhao Q, He X, Li W, Zhang Q, Hu X. Gut microbiota-derived 5-hydroxyindoleacetic acid from pumpkin polysaccharides supplementation alleviates colitis via MAPKs-PPARγ/NF-κB inhibition. Int J Biol Macromol 2024; 264:130385. [PMID: 38395290 DOI: 10.1016/j.ijbiomac.2024.130385] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2023] [Revised: 02/16/2024] [Accepted: 02/20/2024] [Indexed: 02/25/2024]
Abstract
Polysaccharides from Pumpkin (Cucurbita moschata Duchesne) (PPs) have many pharmacological activities, including anti-oxidant, immune, and intestinal microbiota regulation. These activities have provided some reminders of its potential therapeutic effect on ulcerative colitis (UC), but this has not yet been confirmed. This study preliminarily confirmed its significant anti-UC activity superior to Salicylazosulfapyridine. The average molecular weight of PPs was 3.10 × 105 Da, and PPs mainly comprised Mannose, Rhamnose, Galacturonic acid, Galactosamine, Glucose, and Xylose with molar ratios of 1.58:3.51:34.54:1.00:3.25:3.02. PPs (50, 100 mg/kg) could significantly resist dextran sodium sulfate induced UC on C57BL/6 mice by improving gut microbiota dysbiosis, such as the changes of relative abundance of Bacteroides, Culturomica, Mucispirillum, Escherichia-Shigella, Alistipes and Helicobacter. PPs also reverse the abnormal inflammatory reaction, including abnormal level changes of TNF-α, IFN-γ, IL-1β, IL-4, IL-6, IL-10, and IL-18. Metabolomic profiling showed that PPs supplementation resulted in the participation of PPAR and MAPK pathways, as well as the increase of 5-hydroxyindole acetic acid (5-HIAA) level. 5-HIAA also exhibited individual and synergistic anti-UC activities in vivo. Furthermore, combination of PPs and 5-HIAA could also elevate the levels of PPARγ in nuclear and inhibit MAPK/NF-ĸB pathway in the colon. This study revealed that PPs and endogenous metabolite 5-HIAA might be developed to treat UC.
Collapse
Affiliation(s)
- Minglan Wu
- Zhejiang Provincial Key Laboratory of Traditional Chinese Medicine for Clinical Evaluation and Translational Research, Zhejiang Provincial Key Laboratory for Drug Evaluation and Clinical Research, Department of Clinical Pharmacy, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China
| | - Qi Wang
- Key Laboratory of Molecular Animal Nutrition of the Ministry of Education, Institute of Feed Science, College of Animal Sciences, Zhejiang University, Hangzhou 310058, Zhejiang Province, China
| | - Xiaodong Li
- Key Laboratory of Molecular Animal Nutrition of the Ministry of Education, Institute of Feed Science, College of Animal Sciences, Zhejiang University, Hangzhou 310058, Zhejiang Province, China
| | - Songxia Yu
- Zhejiang Provincial Key Laboratory of Traditional Chinese Medicine for Clinical Evaluation and Translational Research, Zhejiang Provincial Key Laboratory for Drug Evaluation and Clinical Research, Department of Clinical Pharmacy, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China
| | - Fan Zhao
- Department of General Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China
| | - Xia Wu
- Zhejiang Provincial Key Laboratory of Traditional Chinese Medicine for Clinical Evaluation and Translational Research, Zhejiang Provincial Key Laboratory for Drug Evaluation and Clinical Research, Department of Clinical Pharmacy, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China
| | - Li Fan
- Zhejiang Provincial Key Laboratory of Traditional Chinese Medicine for Clinical Evaluation and Translational Research, Zhejiang Provincial Key Laboratory for Drug Evaluation and Clinical Research, Department of Clinical Pharmacy, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China
| | - Xueling Liu
- Zhejiang Provincial Key Laboratory of Traditional Chinese Medicine for Clinical Evaluation and Translational Research, Zhejiang Provincial Key Laboratory for Drug Evaluation and Clinical Research, Department of Clinical Pharmacy, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China
| | - Qingwei Zhao
- Zhejiang Provincial Key Laboratory of Traditional Chinese Medicine for Clinical Evaluation and Translational Research, Zhejiang Provincial Key Laboratory for Drug Evaluation and Clinical Research, Department of Clinical Pharmacy, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China
| | - Xuelin He
- Kidney Disease Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China
| | - Weifen Li
- Key Laboratory of Molecular Animal Nutrition of the Ministry of Education, Institute of Feed Science, College of Animal Sciences, Zhejiang University, Hangzhou 310058, Zhejiang Province, China.
| | - Qiao Zhang
- Zhejiang Provincial Key Laboratory of Traditional Chinese Medicine for Clinical Evaluation and Translational Research, Zhejiang Provincial Key Laboratory for Drug Evaluation and Clinical Research, Department of Clinical Pharmacy, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.
| | - Xingjiang Hu
- Zhejiang Provincial Key Laboratory of Traditional Chinese Medicine for Clinical Evaluation and Translational Research, Zhejiang Provincial Key Laboratory for Drug Evaluation and Clinical Research, Department of Clinical Pharmacy, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.
| |
Collapse
|
4
|
Song MF, Ma LY, Shen C, Zhao Q, Zhao CY. [Liver cancer treatment with mitochondrial homeostasis]. Zhonghua Gan Zang Bing Za Zhi 2024; 32:257-261. [PMID: 38584111 DOI: 10.3760/cma.j.cn501113-20231107-00175] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 04/09/2024]
Abstract
Systemic treatment, including molecular targeted therapy, immunotherapy, and chemotherapy, is an important means of achieving long-term survival in patients with intermediate-and advanced-stage liver cancer. However, some patients are insensitive to treatment and even develop drug resistance. Mitochondria are the center of cellular energy metabolism and, at the same time, are the priority targets for systemic therapy. Mitochondrial homeostasis plays an important role in the treatment of liver cancer. The relationship between the two advances is elucidated so as to provide better ideas for the clinical treatment of liver cancer.
Collapse
Affiliation(s)
- M F Song
- Department of Infectious Disease, the Third Hospital of Hebei Medical University, Shijiazhuang 050051, China
| | - L Y Ma
- Department of Infectious Disease, the Third Hospital of Hebei Medical University, Shijiazhuang 050051, China
| | - C Shen
- Department of Infectious Disease, the Third Hospital of Hebei Medical University, Shijiazhuang 050051, China
| | - Q Zhao
- Quality Management and Control Office, the Third Hospital of Hebei Medical University, Shijiazhuang 050051, China
| | - C Y Zhao
- Department of Infectious Disease, the Third Hospital of Hebei Medical University, Shijiazhuang 050051, China
| |
Collapse
|
5
|
Zhang SY, Wei Z, Zhang PQ, Zhao Q, Li M, Bai XH, Wu K, Nie YB, Ding YY, Wang JR, Zhang Y, Su XD, Yao ZE. Neutron-gamma discrimination with broaden the lower limit of energy threshold using BP neural network. Appl Radiat Isot 2024; 205:111179. [PMID: 38217939 DOI: 10.1016/j.apradiso.2024.111179] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2023] [Revised: 12/28/2023] [Accepted: 01/03/2024] [Indexed: 01/15/2024]
Abstract
Neutron-gamma discrimination is a tough and significative in experimental neutrons measurements procedure, especially for low-energy neutrons signal discrimination. In this work, based on the Pulse Shape Discrimination (PSD) and Back-Propagation (BP) artificial neural networks, a neutron-gamma discrimination method is developed to broaden the lower limit of energy threshold with the hidden layer of 20 neurons. Compared with neutron-gamma discrimination method based on PSD only, the developed neutron-gamma discrimination method based on the PSD and BP-ANN can discriminate neutron and gamma-ray signals with low energy threshold, which can discriminate signals up to 99.93%. Moreover, this work can reduce the energy threshold from 350 keV to 70 keV, as well as the acquired data utilization increased from 60% to more than 99.9%, which overcome the hardware limitations and distinguish neutron and gamma-ray signals, effectively. The developed neutron-gamma discrimination method and the trained neural network can be directly used to other experimental neutrons measurements.
Collapse
Affiliation(s)
- S Y Zhang
- School of Nuclear Science and Technology, Lanzhou University, Lanzhou, 730000, China
| | - Z Wei
- School of Nuclear Science and Technology, Lanzhou University, Lanzhou, 730000, China; Engineering Research Center for Neutron Application, Ministry of Education, Lanzhou University, Lanzhou, 730000, China.
| | - P Q Zhang
- School of Nuclear Science and Technology, Lanzhou University, Lanzhou, 730000, China
| | - Q Zhao
- China Institute of Atomic Energy, Beijing, 102413, China
| | - M Li
- School of Nuclear Science and Technology, Lanzhou University, Lanzhou, 730000, China
| | - X H Bai
- School of Nuclear Science and Technology, Lanzhou University, Lanzhou, 730000, China
| | - K Wu
- School of Nuclear Science and Technology, Lanzhou University, Lanzhou, 730000, China
| | - Y B Nie
- China Institute of Atomic Energy, Beijing, 102413, China
| | - Y Y Ding
- China Institute of Atomic Energy, Beijing, 102413, China
| | - J R Wang
- School of Nuclear Science and Technology, Lanzhou University, Lanzhou, 730000, China; Engineering Research Center for Neutron Application, Ministry of Education, Lanzhou University, Lanzhou, 730000, China
| | - Y Zhang
- School of Nuclear Science and Technology, Lanzhou University, Lanzhou, 730000, China; Engineering Research Center for Neutron Application, Ministry of Education, Lanzhou University, Lanzhou, 730000, China
| | - X D Su
- School of Nuclear Science and Technology, Lanzhou University, Lanzhou, 730000, China; Engineering Research Center for Neutron Application, Ministry of Education, Lanzhou University, Lanzhou, 730000, China
| | - Z E Yao
- School of Nuclear Science and Technology, Lanzhou University, Lanzhou, 730000, China; Engineering Research Center for Neutron Application, Ministry of Education, Lanzhou University, Lanzhou, 730000, China
| |
Collapse
|
6
|
Zhu D, Zhao Q, Guo S, Bai L, Yang S, Zhao Y, Xu Y, Zhou X. Efficacy of preventive interventions against ventilator-associated pneumonia in critically ill patients: an umbrella review of meta-analyses. J Hosp Infect 2024; 145:174-186. [PMID: 38295905 DOI: 10.1016/j.jhin.2023.12.017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2023] [Revised: 12/13/2023] [Accepted: 12/26/2023] [Indexed: 02/15/2024]
Abstract
Many meta-analyses have assessed the efficacy of preventive interventions against ventilator-associated pneumonia (VAP) in critically ill patients. However, there has been no comprehensive analysis of the strength and quality of evidence to date. Systematic reviews of randomized and quasi-randomized controlled trials, which evaluated the effect of preventive strategies on the incidence of VAP in critically ill patients receiving mechanical ventilation for at least 48 h, were included in this article. We identified a total of 34 interventions derived from 31 studies. Among these interventions, 19 resulted in a significantly reduced incidence of VAP. Among numerous strategies, only selective decontamination of the digestive tract (SDD) was supported by highly suggestive (Class II) evidence (risk ratio (RR)=0.439, 95% CI: 0.362-0.532). Based on data from the sensitivity analysis, the evidence for the efficacy of non-invasive ventilation in weaning from mechanical ventilation (NIV) was upgraded from weak (Class IV) to highly suggestive (Class II) (RR=0.32, 95% CI: 0.22-0.46). All preventive interventions were not supported by robust evidence for reducing mortality. Early mobilization exhibited suggestive (Class III) evidence in shortening both intensive length of stay (LOS) in the intensive care unit (ICU) (mean difference (MD)=-0.85, 95% CI: -1.21 to -0.49) and duration of mechanical ventilation (MD=-1.02, 95% CI: -1.41 to -0.63). In conclusion, SDD and NIV are supported by robust evidence for prevention against VAP, while early mobilization has been shown to significantly shorten the LOS in the ICU and the duration of mechanical ventilation. These three strategies are recommendable for inclusion in the ventilator bundle to lower the risk of VAP and improve the prognosis of critically ill patients.
Collapse
Affiliation(s)
- D Zhu
- Affiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu Province Hospital of Chinese Medicine, Nanjing, China
| | - Q Zhao
- Affiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu Province Hospital of Chinese Medicine, Nanjing, China
| | - S Guo
- Affiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu Province Hospital of Chinese Medicine, Nanjing, China
| | - L Bai
- Affiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu Province Hospital of Chinese Medicine, Nanjing, China
| | - S Yang
- Affiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu Province Hospital of Chinese Medicine, Nanjing, China
| | - Y Zhao
- Affiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu Province Hospital of Chinese Medicine, Nanjing, China
| | - Y Xu
- School of Chinese Medicine, Nanjing University of Chinese Medicine, Nanjing, China.
| | - X Zhou
- Affiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu Province Hospital of Chinese Medicine, Nanjing, China; Department of Respiratory and Critical Care Medicine, Jiangsu Province Hospital of Chinese Medicine, Nanjing, China.
| |
Collapse
|
7
|
Yan X, He X, Yang X, Zhao Q, Lou Y. The development and validation of a liquid chromatography tandem mass spectrometry method for the quantification of selinexor and its application in Chinese multiple myeloma patients. Anal Methods 2024; 16:1050-1057. [PMID: 38269419 DOI: 10.1039/d3ay02166a] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/26/2024]
Abstract
Selinexor is a nuclear exportin-1 (XPO1) inhibitor that has been approved for the treatment of multiple myeloma patients. However, sustained use of selinexor may result in some undesirable consequences. Furthermore, selinexor has moderate inter-patient variability. Herein, we developed an ultrahigh-performance liquid chromatography tandem mass spectrometry method for measuring selinexor levels in human plasma ranging from 1 to 1000 ng mL-1. Furthermore, the developed approach was validated in accordance with FDA criteria. The established approach demonstrated inter-day and intra-day precision, expressed as the relative standard deviation, of less than 8%, with accuracies of less than 6%, expressed as relative error. The results showed that the protein depletion was quite complete for selinexor extraction, with recoveries ranging from 85.89 to 108.38%. The validated method facilitates the quantitation of selinexor in multiple myeloma patients. The selinexor plasma concentration exhibits obvious inter-patient' variability after administration. Thus, it is necessary to make a personalized prescription through therapeutic drug monitoring. Furthermore, the change in platelet counts before and after selinexor treatment was shown to be related to the plasma concentration at 3 h after administration, which provides the basis for therapeutic drug monitoring sampling time points and a method for predicting the occurrence of thrombocytopenia. In conclusion, the developed method can be used for the quantification of the plasma concentration of selinexor, and it is of great significance to conduct therapeutic drug monitoring for patients taking selinexor in order to enhance therapeutic effects and prevent the occurrence of adverse reactions.
Collapse
Affiliation(s)
- Xiaoting Yan
- Key Laboratory for Drug Evaluation and Clinical Research of Zhejiang Province, Department of Clinical Phamacy, The First Affiliated Hospital, College of Medicine, Zhejiang University, 79 QingChun Road, Hangzhou 310000, China.
| | - Xiaoying He
- Key Laboratory for Drug Evaluation and Clinical Research of Zhejiang Province, Department of Clinical Phamacy, The First Affiliated Hospital, College of Medicine, Zhejiang University, 79 QingChun Road, Hangzhou 310000, China.
| | - Xi Yang
- Key Laboratory for Drug Evaluation and Clinical Research of Zhejiang Province, Department of Clinical Phamacy, The First Affiliated Hospital, College of Medicine, Zhejiang University, 79 QingChun Road, Hangzhou 310000, China.
| | - Qingwei Zhao
- Key Laboratory for Drug Evaluation and Clinical Research of Zhejiang Province, Department of Clinical Phamacy, The First Affiliated Hospital, College of Medicine, Zhejiang University, 79 QingChun Road, Hangzhou 310000, China.
| | - Yan Lou
- Key Laboratory for Drug Evaluation and Clinical Research of Zhejiang Province, Department of Clinical Phamacy, The First Affiliated Hospital, College of Medicine, Zhejiang University, 79 QingChun Road, Hangzhou 310000, China.
| |
Collapse
|
8
|
Lei LY, Qin L, Wang ZG, Wang J, Zhao Q, Ji CQ, Chen B, Zhang QJ, Zhou F, Wu M, Zhou JY, Wang WJ. [Study of the effects of dietary patterns on glycemic control in community type 2 diabetic mellitus patients]. Zhonghua Liu Xing Bing Xue Za Zhi 2024; 45:242-249. [PMID: 38413064 DOI: 10.3760/cma.j.cn112338-20230706-00418] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 02/29/2024]
Abstract
Objective: To understand the impact of diet on glycemic control in community-managed patients with type 2 diabetes mellitus (T2DM) and provide evidence for implementing prevention strategies and measures for diabetes patients. Methods: Eight communities were randomly selected from Changshu and Wuhan in 2015, and T2DM patients managed in the community were selected to conduct questionnaire surveys, physical measurements, and blood glucose testing. Factor analysis was used to obtain dietary patterns. A binary logistic regression model was used to analyze the factors affecting glycemic control. Results: Finally, 1 818 T2DM patients were included, and the control rate of FPG was 57.59% (95%CI: 55.30%-59.86%), and the control rate of 2 h postprandial blood glucose (2 h PBG) was 24.90% (95%CI: 22.93%- 26.91%). Five dietary patterns were obtained by factor analysis: animal food pattern, fruit-aquatic products-potato patterns, vegetable-grain pattern, egg-milk-bean pattern, and oil-salt patterns. No-conditional multivariate logistic regression analysis showed that after adjusting for confounding factors, the reduced probability of FPG control was related to animal food pattern (OR=0.71, 95%CI: 0.52-0.98) and fruit-aquatic products-potato patterns (OR=0.71, 95%CI: 0.51-0.97). The decrease in the 2 h PBG control probability was related to fruit-aquatic products-potato patterns (OR=0.60, 95%CI: 0.40-0.90). The increased probability of FPG and 2 h postprandial glucose control were both related to vegetable-grain pattern (OR=1.41, 95%CI: 1.03-1.94; OR=1.68, 95%CI: 1.13-2.51) and egg-milk-bean pattern (OR=1.75, 95%CI: 1.25-2.46; OR=1.56, 95%CI: 1.00-2.42). Compared with the Q4 group of egg-milk-bean pattern, the FPG control rate of the combination of "fruit-aquatic products-potato pattern (Q4 group), vegetable-grain pattern (Q2 group), egg-milk-bean pattern (Q3 group)" was higher (OR=6.79, 95%CI: 1.15-40.23, P=0.035). Compared with the Q4 group of vegetable-grain pattern, the combination of "fruit-aquatic products-potato pattern (Q4 group), vegetable-grain pattern (Q3 group), egg-milk-bean pattern (Q2 group), oil-salt pattern (Q2 group)" had higher control rate of 2 h PBG (OR=12.78, 95%CI: 1.26-130.05, P=0.031). Conclusions: A proper combination of dietary patterns and dietary patterns are more conducive to the control of FPG and 2 h PBG in T2DM patients managed in the communities of Wuhan and Changshu. Patient nutrition education should be strengthened, and the food-matching ability of patients should be improved.
Collapse
Affiliation(s)
- L Y Lei
- Obesity and Metabolic Disease Prevention and Control Room, National Center for Chronic and Non-communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 100050, China
| | - L Qin
- Obesity and Metabolic Disease Prevention and Control Room, National Center for Chronic and Non-communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 100050, China Department for Surveillance and Early Earning, Beijing Center for Public Health Emergency Management, Beijing 100053, China
| | - Z G Wang
- Obesity and Metabolic Disease Prevention and Control Room, National Center for Chronic and Non-communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 100050, China Health Supervision Institute, Langfang Economic and Technological Development Zone, Langfang 065001, China
| | - J Wang
- Obesity and Metabolic Disease Prevention and Control Room, National Center for Chronic and Non-communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 100050, China Key Laboratory of Environment and Population Health, National Institute of Environmental Health, Chinese Center for Disease Conrtol and Prevention, Beijing 100021, China
| | - Q Zhao
- Obesity and Metabolic Disease Prevention and Control Room, National Center for Chronic and Non-communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 100050, China Department of Infectious Disease and Endemic Disease Control, Beijing Tongzhou District Center for Disease Control and Prevention, Beijing 101100, China
| | - C Q Ji
- Obesity and Metabolic Disease Prevention and Control Room, National Center for Chronic and Non-communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 100050, China Chronic Disease Prevention and Treatment Department, Beijing Tongzhou District Center for Disease Control and Prevention, Beijing 101100, China
| | - B Chen
- Cancer and Key Chronic Disease Control and Prevention Laboratory, National Center for Chronic and Non-communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention,Beijing 100050, China
| | - Q J Zhang
- Institute of Chronic and Non-communicable Diseases, Hubei Provincial Center for Disease Control and Prevention, Wuhan 430079, China
| | - F Zhou
- Institute of Chronic and Non-communicable Diseases, Hubei Provincial Center for Disease Control and Prevention, Wuhan 430079, China
| | - M Wu
- Department of Chronic and Non-communicable Disease Control and Prevention, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing 210009, China
| | - J Y Zhou
- Department of Chronic and Non-communicable Disease Control and Prevention, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing 210009, China
| | - W J Wang
- Obesity and Metabolic Disease Prevention and Control Room, National Center for Chronic and Non-communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 100050, China
| |
Collapse
|
9
|
Xie Y, Jiang Y, Wu Y, Su X, Zhu D, Gao P, Yuan H, Xiang Y, Wang J, Zhao Q, Xu K, Zhang T, Man Q, Chen X, Zhao G, Jiang Y, Suo C. Association of serum lipids and abnormal lipid score with cancer risk: a population-based prospective study. J Endocrinol Invest 2024; 47:367-376. [PMID: 37458930 DOI: 10.1007/s40618-023-02153-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/03/2023] [Accepted: 07/02/2023] [Indexed: 02/13/2024]
Abstract
BACKGROUND Serum lipid levels are associated with cancer risk. However, there still have uncertainties about the single and combined effects of low lipid levels on cancer risk. METHODS A prospective cohort study of 33,773 adults in Shanghai between 2016 and 2017 was conducted. Total cholesterol (TC), triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C) levels were measured. Cox proportional hazard models were used to assess the association of single and combined lipids with overall, lung, colon, rectal, thyroid gland, stomach, and female breast cancers. The effect of the combination of abnormal lipid score and lifestyle on cancer was also estimated. RESULTS A total of 926 incident cancer cases were identified. In the RCS analysis, hazard ratios (HRs) of overall cancer for individuals with TC < 5.18 mmol/L or with LDL-C < 3.40 mmol/L were higher. Low TC was associated with higher colorectal cancer risk (HR [95% CI] = 1.76 [1.09-2.84]) and low HDL-C increased thyroid cancer risk by 90%. Abnormal lipid score was linearly and positively associated with cancer risk, and smokers with high abnormal lipid scores had a higher cancer risk, compared to non-smokers with low abnormal lipid scores (P < 0.05). CONCLUSIONS Low TC levels were associated with an increased risk of overall and colorectal cancer. More attention should be paid to participants with high abnormal lipid scores and unhealthy lifestyles who may have a higher risk of developing cancer. Determining the specific and comprehensive lipid combinations that affect tumorigenesis remains a valuable challenge.
Collapse
Affiliation(s)
- Y Xie
- Department of Epidemiology, School of Public Health and Key Laboratory of Public Health Safety of Ministry of Education, Fudan University, Shanghai, China
| | - Y Jiang
- Songjiang District Center for Disease Control and Prevention, Shanghai, China
| | - Y Wu
- Songjiang District Center for Disease Control and Prevention, Shanghai, China
| | - X Su
- Songjiang District Center for Disease Control and Prevention, Shanghai, China
| | - D Zhu
- Department of Epidemiology, School of Public Health and Key Laboratory of Public Health Safety of Ministry of Education, Fudan University, Shanghai, China
| | - P Gao
- State Key Laboratory of Genetic Engineering, Human Phenome Institute, and School of Life Sciences, Fudan University, Shanghai, China
| | - H Yuan
- State Key Laboratory of Genetic Engineering, Human Phenome Institute, and School of Life Sciences, Fudan University, Shanghai, China
| | - Y Xiang
- Department of Epidemiology, School of Public Health and Key Laboratory of Public Health Safety of Ministry of Education, Fudan University, Shanghai, China
| | - J Wang
- Department of Epidemiology, School of Public Health and Key Laboratory of Public Health Safety of Ministry of Education, Fudan University, Shanghai, China
| | - Q Zhao
- Department of Social Medicine, School of Public Health, Fudan University, Shanghai, China
| | - K Xu
- Department of Biostatistics, School of Public Health, Fudan University, Shanghai, China
| | - T Zhang
- Department of Epidemiology, School of Public Health and Key Laboratory of Public Health Safety of Ministry of Education, Fudan University, Shanghai, China
- Fudan University Taizhou Institute of Health Sciences, Taizhou, Jiangsu, China
- Yiwu Research Institute of Fudan University, Yiwu, Zhejiang, China
| | - Q Man
- Department of Clinical Laboratory, School of Medicine, Shanghai Fourth People's Hospital, Tongji University, Shanghai, China
| | - X Chen
- Fudan University Taizhou Institute of Health Sciences, Taizhou, Jiangsu, China
- Yiwu Research Institute of Fudan University, Yiwu, Zhejiang, China
- State Key Laboratory of Genetic Engineering, Zhangjiang Fudan International Innovation Center, and National Clinical Research Center for Aging and Medicine, Human Phenome Institute, Huashan Hospital, Fudan University, Shanghai, China
| | - G Zhao
- Department of Epidemiology, School of Public Health and Key Laboratory of Public Health Safety of Ministry of Education, Fudan University, Shanghai, China
| | - Y Jiang
- State Key Laboratory of Genetic Engineering, Human Phenome Institute, and School of Life Sciences, Fudan University, Shanghai, China
- Fudan University Taizhou Institute of Health Sciences, Taizhou, Jiangsu, China
| | - C Suo
- Department of Epidemiology, School of Public Health and Key Laboratory of Public Health Safety of Ministry of Education, Fudan University, Shanghai, China.
- Fudan University Taizhou Institute of Health Sciences, Taizhou, Jiangsu, China.
- Shanghai Institute of Infectious Disease and Biosecurity, Shanghai, China.
| |
Collapse
|
10
|
Yin J, Chen Z, You N, Li F, Zhang H, Xue J, Ma H, Zhao Q, Yu L, Zeng S, Zhu F. VARIDT 3.0: the phenotypic and regulatory variability of drug transporter. Nucleic Acids Res 2024; 52:D1490-D1502. [PMID: 37819041 PMCID: PMC10767864 DOI: 10.1093/nar/gkad818] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2023] [Revised: 09/01/2023] [Accepted: 09/27/2023] [Indexed: 10/13/2023] Open
Abstract
The phenotypic and regulatory variability of drug transporter (DT) are vital for the understanding of drug responses, drug-drug interactions, multidrug resistances, and so on. The ADME property of a drug is collectively determined by multiple types of variability, such as: microbiota influence (MBI), transcriptional regulation (TSR), epigenetics regulation (EGR), exogenous modulation (EGM) and post-translational modification (PTM). However, no database has yet been available to comprehensively describe these valuable variabilities of DTs. In this study, a major update of VARIDT was therefore conducted, which gave 2072 MBIs, 10 610 TSRs, 46 748 EGRs, 12 209 EGMs and 10 255 PTMs. These variability data were closely related to the transportation of 585 approved and 301 clinical trial drugs for treating 572 diseases. Moreover, the majority of the DTs in this database were found with multiple variabilities, which allowed a collective consideration in determining the ADME properties of a drug. All in all, VARIDT 3.0 is expected to be a popular data repository that could become an essential complement to existing pharmaceutical databases, and is freely accessible without any login requirement at: https://idrblab.org/varidt/.
Collapse
Affiliation(s)
- Jiayi Yin
- College of Pharmaceutical Sciences, Department of Clinical Pharmacy, The First Affiliated Hospital, Zhejiang University School of Medicine, National Key Laboratory of Advanced Drug Delivery and Release Systems, Zhejiang University, Hangzhou 310058, China
- Innovation Institute for Artificial Intelligence in Medicine of Zhejiang University, Alibaba-Zhejiang University Joint Research Center of Future Digital Healthcare, Hangzhou 330110, China
| | - Zhen Chen
- College of Pharmaceutical Sciences, Department of Clinical Pharmacy, The First Affiliated Hospital, Zhejiang University School of Medicine, National Key Laboratory of Advanced Drug Delivery and Release Systems, Zhejiang University, Hangzhou 310058, China
| | - Nanxin You
- College of Pharmaceutical Sciences, Department of Clinical Pharmacy, The First Affiliated Hospital, Zhejiang University School of Medicine, National Key Laboratory of Advanced Drug Delivery and Release Systems, Zhejiang University, Hangzhou 310058, China
| | - Fengcheng Li
- College of Pharmaceutical Sciences, Department of Clinical Pharmacy, The First Affiliated Hospital, Zhejiang University School of Medicine, National Key Laboratory of Advanced Drug Delivery and Release Systems, Zhejiang University, Hangzhou 310058, China
- The Children's Hospital, Zhejiang University School of Medicine, Zhejiang University, Hangzhou 310052, China
| | - Hanyu Zhang
- College of Pharmaceutical Sciences, Department of Clinical Pharmacy, The First Affiliated Hospital, Zhejiang University School of Medicine, National Key Laboratory of Advanced Drug Delivery and Release Systems, Zhejiang University, Hangzhou 310058, China
| | - Jia Xue
- College of Pharmaceutical Sciences, Department of Clinical Pharmacy, The First Affiliated Hospital, Zhejiang University School of Medicine, National Key Laboratory of Advanced Drug Delivery and Release Systems, Zhejiang University, Hangzhou 310058, China
| | - Hui Ma
- College of Pharmaceutical Sciences, Department of Clinical Pharmacy, The First Affiliated Hospital, Zhejiang University School of Medicine, National Key Laboratory of Advanced Drug Delivery and Release Systems, Zhejiang University, Hangzhou 310058, China
| | - Qingwei Zhao
- College of Pharmaceutical Sciences, Department of Clinical Pharmacy, The First Affiliated Hospital, Zhejiang University School of Medicine, National Key Laboratory of Advanced Drug Delivery and Release Systems, Zhejiang University, Hangzhou 310058, China
| | - Lushan Yu
- College of Pharmaceutical Sciences, Department of Clinical Pharmacy, The First Affiliated Hospital, Zhejiang University School of Medicine, National Key Laboratory of Advanced Drug Delivery and Release Systems, Zhejiang University, Hangzhou 310058, China
| | - Su Zeng
- College of Pharmaceutical Sciences, Department of Clinical Pharmacy, The First Affiliated Hospital, Zhejiang University School of Medicine, National Key Laboratory of Advanced Drug Delivery and Release Systems, Zhejiang University, Hangzhou 310058, China
| | - Feng Zhu
- College of Pharmaceutical Sciences, Department of Clinical Pharmacy, The First Affiliated Hospital, Zhejiang University School of Medicine, National Key Laboratory of Advanced Drug Delivery and Release Systems, Zhejiang University, Hangzhou 310058, China
- Innovation Institute for Artificial Intelligence in Medicine of Zhejiang University, Alibaba-Zhejiang University Joint Research Center of Future Digital Healthcare, Hangzhou 330110, China
| |
Collapse
|
11
|
Nian Z, Zhao Q, He Y, Xie R, Liu W, Chen T, Huang S, Dong L, Huang R, Yang L. Efficacy and Safety of First-line Therapies for Advanced Unresectable Oesophageal Squamous Cell Cancer: a Systematic Review and Network Meta-analysis. Clin Oncol (R Coll Radiol) 2024; 36:30-38. [PMID: 37827946 DOI: 10.1016/j.clon.2023.09.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2023] [Revised: 08/27/2023] [Accepted: 09/21/2023] [Indexed: 10/14/2023]
Abstract
AIM To compare the clinical efficacy and safety of first-line treatments for advanced unresectable oesophageal squamous cell cancer. MATERIALS AND METHODS A systematic review and network meta-analysis was carried out by retrieving and retaining relevant literature from databases. The studies were randomised controlled trials comparing first-line treatments for advanced unresectable oesophageal squamous cell cancer. A Bayesian network meta-analysis was used to assess clinical outcomes. RESULTS Nine studies including 4499 patients receiving first-line treatments were analysed. For all populations, toripalimab plus chemotherapy tended to provide the best overall survival (hazard ratio 0.58, 95% confidence intervals 0.43-0.78) and sintilimab plus chemotherapy provided the best progression-free survival (0.56, 0.46-0.68). Nivolumab plus chemotherapy presented the best objective response rate (odds ratio 2.45, 1.78-3.42) and camrelizumab plus chemotherapy (0.47, 0.29-0.74) appeared to be the safest. Sintilimab plus chemotherapy (0.55, 0.40-0.75) and nivolumab (0.54, 0.37-0.80) plus chemotherapy had the best overall survival in programmed death ligand 1 (PD-L1) tumour proportion score <1% and ≥1% subgroups. Toripalimab plus chemotherapy (0.61, 0.40-0.93) and pembrolizumab (0.57, 0.43-0.75) were the best in overall survival in combined positive score <10 and ≥10 subgroups, respectively. Toripalimab plus chemotherapy showed the best overall survival in the Asian group; pembrolizumab presented better overall survival in the Asian population than the non-Asian group. CONCLUSION Most immunotherapy combined with chemotherapy showed superior clinical benefits and sintilimab plus chemotherapy, toripalimab plus chemotherapy and tislelizumab plus chemotherapy had better comprehensive clinical efficacy. PD-L1 expression detection and ethnicity differences are still of great significance and most suitable regimens varied from each subgroup.
Collapse
Affiliation(s)
- Z Nian
- School of Pharmacy, Fujian Medical University, Fuzhou, China
| | - Q Zhao
- Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China
| | - Y He
- School of Pharmacy, Fujian Medical University, Fuzhou, China
| | - R Xie
- Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China
| | - W Liu
- Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China
| | - T Chen
- Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China
| | - S Huang
- Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China
| | - L Dong
- Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China
| | - R Huang
- Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China
| | - L Yang
- Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.
| |
Collapse
|
12
|
Guo HH, Song BY, Wang XR, Cui JX, Zhang ZB, Wang BY, Liu Y, Tan BB, Zhao Q. [A case of diaphragmatic hemangioma misdiagnosed as gastrointestinal stromal tumor of stomach]. Zhonghua Wei Chang Wai Ke Za Zhi 2023; 26:1194-1195. [PMID: 38110283 DOI: 10.3760/cma.j.cn441530-20230613-00204] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/20/2023]
|
13
|
Jin ML, Mamute M, Shapaermaimaiti H, Li JX, Cao J, Li HY, Meng FH, Zhao Q, Ji HY, Abuzhalihan J, Aigaixi A, Lu XF, Fu ZY. [Analysis of the prevalence of dyslipidemia and correlative factors in Tajik population in Pamir Plateau of Xinjiang]. Zhonghua Xin Xue Guan Bing Za Zhi 2023; 51:1240-1246. [PMID: 38123206 DOI: 10.3760/cma.j.cn112148-20231007-00231] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 12/23/2023]
Abstract
Objective: To investigate the prevalence of dyslipidemia and the level of blood lipids among Tajik people in Pamir Plateau, Xinjiang, and explore the related factors of dyslipidemia. Methods: It is a retrospective cross-sectional study. A multi-stage cluster random sampling survey was conducted among 5 635 Tajiks over 18 years old in Tashkorgan Tajik Autonomous County, Xinjiang Province from May to October 2021. Data were collected through questionnaire survey (general information, medical history, and personal history), physical examination (height, weight, waist, and blood pressure) and blood test (total cholesterol (TC), triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), and high-density cholesterol (HDL-C)) to analyze the dyslipidemia and its risk factors among Tajiks. Results: The age of Tajik participants was (41.9±15.0) years, including 2 726 males (48.4%). The prevalence of borderline high TC, high LDL-C and high TG levels were 17.2%, 14.7% and 8.9%, respectively. The prevalence of high TC, high LDL-C, high TG and low HDL-C were 4.1%, 4.9%, 9.4% and 32.4%, respectively, and the prevalence of dyslipidemia was 37.0%. There is a positive correlation between male,higher education level, higher body mass index (BMI) value,waist circumference, living in town, smoking and dyslipidemia. Conclusions: The low prevalence of high TC, high LDL-C, high TG and high prevalence of low HDL-C was a major characteristic of Tajik people in Pamir Plateau of Xinjiang. The lower rates of overweight and obesity may be one of the reasons for the lower prevalence of dyslipidemia among Tajik.
Collapse
Affiliation(s)
- M L Jin
- Department of Cardiology and State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, First Affiliated Hospital of Xinjiang Medical University, Urumqi 830011, China
| | - Mawusumu Mamute
- Department of Urology, First People's Hospital of Kashgar District, Kashgar 844099, China
| | - Hebali Shapaermaimaiti
- Disease Control and Prevention Center of Tashkurgan Tajik Autonomous County, Kashgar 845250, China
| | - J X Li
- Department of Epidemiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China
| | - J Cao
- Department of Epidemiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China
| | - H Y Li
- Department of Cardiology, First Affiliated Hospital of Xinjiang Medical University, Urumqi 830011, China
| | - F H Meng
- Department of Cardiology of Affiliated Hospital of Jining Medical University, Jining 272007, China
| | - Q Zhao
- Department of Cardiology, First Affiliated Hospital of Xinjiang Medical University, Urumqi 830011, China
| | - H Y Ji
- Department of Cardiology, First Affiliated Hospital of Xinjiang Medical University, Urumqi 830011, China
| | - Jialin Abuzhalihan
- Department of Cardiology, First Affiliated Hospital of Xinjiang Medical University, Urumqi 830011, China
| | - Abuduhalike Aigaixi
- Health Commission of Tashkurgan Tajik Autonomous County, Kashgar 845250, China
| | - X F Lu
- Department of Epidemiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China
| | - Z Y Fu
- Department of Cardiology and State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, First Affiliated Hospital of Xinjiang Medical University, Urumqi 830011, China
| |
Collapse
|
14
|
Lv D, Grayling MJ, Zhang X, Zhao Q, Zheng H. A Bayesian approach to pilot-pivotal trials for bioequivalence assessment. BMC Med Res Methodol 2023; 23:301. [PMID: 38114931 PMCID: PMC10729540 DOI: 10.1186/s12874-023-02120-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2022] [Accepted: 12/07/2023] [Indexed: 12/21/2023] Open
Abstract
BACKGROUND To demonstrate bioequivalence between two drug formulations, a pilot trial is often conducted prior to a pivotal trial to assess feasibility and gain preliminary information about the treatment effect. Due to the limited sample size, it is not recommended to perform significance tests at the conventional 5% level using pilot data to determine if a pivotal trial should take place. Whilst some authors suggest to relax the significance level, a Bayesian framework provides an alternative for informing the decision-making. Moreover, a Bayesian approach also readily permits possible incorporation of pilot data in priors for the parameters that underpin the pivotal trial. METHODS We consider two-sequence, two-period crossover designs that compare test (T) and reference (R) treatments. We propose a robust Bayesian hierarchical model, embedded with a scaling factor, to elicit a Go/No-Go decision using predictive probabilities. Following a Go decision, the final analysis to formally establish bioequivalence can leverage both the pilot and pivotal trial data jointly. A simulation study is performed to evaluate trial operating characteristics. RESULTS Compared with conventional procedures, our proposed method improves the decision-making to correctly allocate a Go decision in scenarios of bioequivalence. By choosing an appropriate threshold, the probability of correctly (incorrectly) making a No-Go (Go) decision can be ensured at a desired target level. Using both pilot and pivotal trial data in the final analysis can result in a higher chance of declaring bioequivalence. The false positive rate can be maintained in situations when T and R are not bioequivalent. CONCLUSIONS The proposed methodology is novel and effective in different stages of bioequivalence assessment. It can greatly enhance the decision-making process in bioequivalence trials, particularly in situations with a small sample size.
Collapse
Affiliation(s)
- Duo Lv
- Department of Clinical Pharmacy, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
- Zhejiang Provincial Key Laboratory for Drug Evaluation and Clinical Research, Hangzhou, China
| | - Michael J Grayling
- Population Health Sciences Institute, Newcastle University, Newcastle, UK
| | - Xinyue Zhang
- Population Health Sciences Institute, Newcastle University, Newcastle, UK
| | - Qingwei Zhao
- Department of Clinical Pharmacy, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
- Zhejiang Provincial Key Laboratory for Drug Evaluation and Clinical Research, Hangzhou, China
| | - Haiyan Zheng
- Department of Mathematical Sciences, University of Bath, Bath, UK.
| |
Collapse
|
15
|
Hoffmann LB, Li B, Zhao Q, Wei W, Leighton LJ, Bredy TW, Pang TY, Hannan AJ. Chronically high stress hormone levels dysregulate sperm long noncoding RNAs and their embryonic microinjection alters development and affective behaviours. Mol Psychiatry 2023:10.1038/s41380-023-02350-2. [PMID: 38114632 DOI: 10.1038/s41380-023-02350-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/30/2023] [Revised: 11/20/2023] [Accepted: 11/27/2023] [Indexed: 12/21/2023]
Abstract
Previous studies on paternal epigenetic inheritance have shown that sperm RNAs play a role in this type of inheritance. The microinjection of sperm small noncoding RNAs into fertilised mouse oocytes induces reprogramming of the early embryo, which is thought to be responsible for the differences observed in adult phenotype. While sperm long noncoding RNAs (lncRNAs) have also been investigated in a previous study, their microinjection into fertilised oocytes did not yield conclusive results regarding their role in modulating brain development and adult behavioural phenotypes. Therefore, in the current study we sought to investigate this further. We used our previously established paternal corticosterone (stress hormone) model to assess sperm lncRNA expression using CaptureSeq, a sequencing technique that is more sensitive than the ones used in other studies in the field. Paternal corticosterone exposure led to dysregulation of sperm long noncoding RNA expression, which encompassed lncRNAs, circular RNAs and transposable element transcripts. Although they have limited functional annotation, bioinformatic approaches indicated the potential of these lncRNAs in regulating brain development and function. We then separated and isolated the sperm lncRNAs and performed microinjections into fertilised oocytes, to generate embryos with modulated lncRNA populations. We observed that the resulting adult offspring had lower body weight and altered anxiety and affective behavioural responses, demonstrating roles for lncRNAs in modulating development and brain function. This study provides novel insights into the roles of lncRNAs in epigenetic inheritance, including impacts on brain development and behaviours of relevance to affective disorders.
Collapse
Affiliation(s)
- L B Hoffmann
- Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, VIC, Australia
- Florey Department of Neuroscience and Mental Health, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Parkville, VIC, Australia
| | - B Li
- Florey Department of Neuroscience and Mental Health, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Parkville, VIC, Australia
| | - Q Zhao
- Cognitive Neuroepigenetics Laboratory, Queensland Brain Institute, The University of Queensland, Brisbane, QLD, Australia
| | - W Wei
- Cognitive Neuroepigenetics Laboratory, Queensland Brain Institute, The University of Queensland, Brisbane, QLD, Australia
| | - L J Leighton
- Cognitive Neuroepigenetics Laboratory, Queensland Brain Institute, The University of Queensland, Brisbane, QLD, Australia
| | - T W Bredy
- Cognitive Neuroepigenetics Laboratory, Queensland Brain Institute, The University of Queensland, Brisbane, QLD, Australia
| | - T Y Pang
- Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, VIC, Australia
- Florey Department of Neuroscience and Mental Health, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Parkville, VIC, Australia
| | - A J Hannan
- Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, VIC, Australia.
- Florey Department of Neuroscience and Mental Health, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Parkville, VIC, Australia.
- Department of Anatomy and Physiology, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Parkville, VIC, Australia.
| |
Collapse
|
16
|
Wang W, Lei LB, Zhao Q, He GD, Ji RQ, Li JK, Zhang LH. [Progress in research of models for predicting the risk of readmission and mortality among patients with acute heart failure]. Zhonghua Liu Xing Bing Xue Za Zhi 2023; 44:2005-2011. [PMID: 38129161 DOI: 10.3760/cma.j.cn112338-20230527-00336] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 12/23/2023]
Abstract
Heart failure is a serious and end-stage status of various heart diseases, characterized by comparatively high rate of readmission and mortality, and has become an important public health issue. The risk of readmission and mortality following discharge of an index hospitalization are key indicators to evaluate the quality of medical care among patients with acute heart failure. Therefore, it is important to carry out risk prediction research for patients with acute heart failure, quantify the disease risk, perform risk stratification, optimize clinical decision-making, elevate patients' quality of life and prognosis, and comprehensively improve the medical quality of acute heart failure. During the past 20 years, foreign researchers have developed dozens of models to predict the risk of acute heart failure readmission and mortality, and Chinese researchers have also developed up to 10 models applicable to the Chinese population. However, there is no recommended risk prediction model for acute heart failure in current clinical guidelines across China. In this report, we aim to introduce the major models for predicting the risk of acute heart failure readmission and mortality from home and abroad, focus on putting forward limitations of established models, and initiating potential directions for future studies from the following aspects: integrate multi-source data, mine emerging biomarkers, establish polygenic risk scores, optimize machine learning methods, promote flexible adjustment, and broaden approaches that applicable for various scenarios. Accordingly, this study will help facilitate domestic research in predicting the risk of readmission and mortality among patients hospitalized for acute heart failure.
Collapse
Affiliation(s)
- W Wang
- National Clinical Research Center for Cardiovascular Diseases, National Center for Cardiovascular Diseases, Fuwai Hospital, Chinese Academy of Medical Sciences, Beijing 100037, China
| | - L B Lei
- National Clinical Research Center for Cardiovascular Diseases, National Center for Cardiovascular Diseases, Fuwai Hospital, Chinese Academy of Medical Sciences, Beijing 100037, China
| | - Q Zhao
- Department of Cardiology, the First Affiliated Hospital of Xinjiang Medical University, Urumqi 830054, China
| | - G D He
- National Clinical Research Center for Cardiovascular Diseases, National Center for Cardiovascular Diseases, Fuwai Hospital, Chinese Academy of Medical Sciences, Beijing 100037, China
| | - R Q Ji
- National Clinical Research Center for Cardiovascular Diseases, National Center for Cardiovascular Diseases, Fuwai Hospital, Chinese Academy of Medical Sciences, Beijing 100037, China
| | - J K Li
- National Clinical Research Center for Cardiovascular Diseases, National Center for Cardiovascular Diseases, Fuwai Hospital, Chinese Academy of Medical Sciences, Beijing 100037, China
| | - L H Zhang
- National Clinical Research Center for Cardiovascular Diseases, National Center for Cardiovascular Diseases, Fuwai Hospital, Chinese Academy of Medical Sciences, Beijing 100037, China
| |
Collapse
|
17
|
Hong W, Fu W, Zhao Q, Xue C, Cai W, Dong N, Shan A. Effects of oleanolic acid on acute liver injury triggered by lipopolysaccharide in broiler chickens. Br Poult Sci 2023; 64:697-709. [PMID: 37697900 DOI: 10.1080/00071668.2023.2251119] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2022] [Revised: 06/21/2023] [Accepted: 07/03/2023] [Indexed: 09/13/2023]
Abstract
1. Infectious injury caused by lipopolysaccharide (LPS), a metabolite of gram-negative bacteria, can induce stress responses in animals and is a significant cause of morbidity and mortality in young birds. The purpose of this study was to investigate the effects of dietary supplementation with oleanolic acid (OA) on acute liver injury in broiler chickens challenged with LPS.2. In total, 120 broiler chickens were randomly divided into six groups and fed a basal diet containing 0, 50, 100, or 200 mg/kg OA or 100 mg/kg aureomycin. On d 15, broiler chickens were injected with either LPS or an equivalent volume of normal saline. Six hours after LPS injection, two broiler chicks were randomly selected for sampling in each replicate.3. The results indicated that dietary aureomycin was ineffective in alleviating LSP-associated liver injury, but protected broiler chickens from LPS-induced liver damage. This promoted a significant reduction in the levels of malondialdehyde and an increase in the levels of superoxide dismutase in liver. In addition, OA was found to cause significant reductions in the relative expression of IL-1β, IL-6, and TNF-α in broiler liver tissues, whereas the relative expression of IL-10 was significantly increased.4. In conclusion, oleanolic acid can alleviate oxidative stress and injury in the livers of broiler chickens induced by lipopolysaccharide. Consequently, oleanolic acid has potential utility as a novel anti-inflammatory and antioxidant feed additive.
Collapse
Affiliation(s)
- W Hong
- The Laboratory of Molecular Nutrition and Immunity, College of Animal Science and Technology, Northeast Agricultural University, Harbin, P. R. China
| | - W Fu
- The Laboratory of Molecular Nutrition and Immunity, College of Animal Science and Technology, Northeast Agricultural University, Harbin, P. R. China
| | - Q Zhao
- The Laboratory of Molecular Nutrition and Immunity, College of Animal Science and Technology, Northeast Agricultural University, Harbin, P. R. China
| | - C Xue
- The Laboratory of Molecular Nutrition and Immunity, College of Animal Science and Technology, Northeast Agricultural University, Harbin, P. R. China
| | - W Cai
- The Laboratory of Molecular Nutrition and Immunity, College of Animal Science and Technology, Northeast Agricultural University, Harbin, P. R. China
| | - N Dong
- The Laboratory of Molecular Nutrition and Immunity, College of Animal Science and Technology, Northeast Agricultural University, Harbin, P. R. China
| | - A Shan
- The Laboratory of Molecular Nutrition and Immunity, College of Animal Science and Technology, Northeast Agricultural University, Harbin, P. R. China
| |
Collapse
|
18
|
Ma T, Meng Z, Ghaffari M, Lv J, Xin H, Zhao Q. Characterization and profiling of the microRNA in small extracellular vesicles isolated from goat milk samples collected during the first week postpartum. JDS Commun 2023; 4:507-512. [PMID: 38045901 PMCID: PMC10692291 DOI: 10.3168/jdsc.2022-0369] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 12/30/2022] [Accepted: 04/06/2023] [Indexed: 12/05/2023]
Abstract
Colostrum contains nutrients, immunoglobulins, and various bioactive compounds such as microRNA (miRNA). Less is known about the temporal changes in miRNA profiles in ruminant milk samples during the first week postpartum. In this study, we characterized and compared the profiles of miRNA in the small extracellular vesicles (sEV) isolated from colostrum (CM, collected immediately after parturition, n = 8) and transition milk (TM, collected 7 d postpartum, n = 8) from eight 1-yr-old Guanzhong dairy goats with a milk yield of approximately 500 kg/year. A total of 192 unique sEV-associated miRNA (transcripts per million >1 at least 4 samples in either CM or TM) were identified in all samples. There were 29 miRNA uniquely identified in the TM samples while no miRNA was uniquely identified in the CM samples. The abundance of the top 10 miRNA accounted for 82.4% ± 4.0% (± SD) of the total abundance, with let-7 families (e.g., let-7a/b/c-5p) being predominant in all samples. The top 10 miRNA were predicted to target 1,008 unique genes that may regulate pathways such as focal adhesion, TGF-β signaling, and axon guidance. The expression patterns of EV miRNA were similar between the 2 sample groups, although the abundance of let-7c-5p and miR-30a-3p was higher, whereas that of let-7i-5p and miR-103-3p was lower in CM than in TM. In conclusion, the core miRNAome identified in the samples from CM and TM may play an important role in cell proliferation, bone homeostasis, and neuronal network formation in newborn goat kids. The lack of differential miRNA expression between the CM and TM samples may be due to a relatively short sampling interval in which diet composition, intake and health status of ewes, and environment were relatively stable.
Collapse
Affiliation(s)
- T. Ma
- Institute of Feed Research, Key Laboratory of Feed Biotechnology of the Ministry of Agriculture and Rural Affairs, Chinese Academy of Agricultural Sciences, Beijing, 100081, China
| | - Z. Meng
- Inner Mongolia Academy of Agriculture and Animal Husbandry Sciences, Hohhot, 010030, China
| | - M.H. Ghaffari
- Institute of Animal Science, University of Bonn, Bonn, 53115, Germany
| | - J. Lv
- College of Animal Sciences and Technology, Northeast Agricultural University, Harbin, 150030, China
| | - H. Xin
- College of Animal Sciences and Technology, Northeast Agricultural University, Harbin, 150030, China
| | - Q. Zhao
- Inner Mongolia Academy of Agriculture and Animal Husbandry Sciences, Hohhot, 010030, China
| |
Collapse
|
19
|
Li X, Yu M, Zhao Q, Yu Y. Prospective therapeutics for intestinal and hepatic fibrosis. Bioeng Transl Med 2023; 8:e10579. [PMID: 38023697 PMCID: PMC10658571 DOI: 10.1002/btm2.10579] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2023] [Revised: 06/17/2023] [Accepted: 07/12/2023] [Indexed: 12/01/2023] Open
Abstract
Currently, there are no effective therapies for intestinal and hepatic fibrosis representing a considerable unmet need. Breakthroughs in pathogenesis have accelerated the development of anti-fibrotic therapeutics in recent years. Particularly, with the development of nanotechnology, the harsh environment of the gastrointestinal tract and inaccessible microenvironment of fibrotic lesions seem to be no longer considered a great barrier to the use of anti-fibrotic drugs. In this review, we comprehensively summarize recent preclinical and clinical studies on intestinal and hepatic fibrosis. It is found that the targets for preclinical studies on intestinal fibrosis is varied, which could be divided into molecular, cellular, and tissues level, although little clinical trials are ongoing. Liver fibrosis clinical trials have focused on improving metabolic disorders, preventing the activation and proliferation of hepatic stellate cells, promoting the degradation of collagen, and reducing inflammation and cell death. At the preclinical stage, the therapeutic strategies have focused on drug targets and delivery systems. At last, promising remedies to the current challenges are based on multi-modal synergistic and targeted delivery therapies through mesenchymal stem cells, nanotechnology, and gut-liver axis providing useful insights into anti-fibrotic strategies for clinical use.
Collapse
Affiliation(s)
- Xin Li
- Department of Clinical Pharmacy, The First Affiliated HospitalZhejiang University School of MedicineHangzhouChina
- Zhejiang Provincial Key Laboratory for Drug Evaluation and Clinical Research, The First Affiliated HospitalZhejiang University School of MedicineHangzhouChina
- Institute of Pharmaceutics, College of Pharmaceutical SciencesZhejiang UniversityHangzhouChina
| | - Mengli Yu
- Department of Gastroenterology, The Fourth Affiliated HospitalZhejiang University School of MedicineYiwuChina
| | - Qingwei Zhao
- Department of Clinical Pharmacy, The First Affiliated HospitalZhejiang University School of MedicineHangzhouChina
- Zhejiang Provincial Key Laboratory for Drug Evaluation and Clinical Research, The First Affiliated HospitalZhejiang University School of MedicineHangzhouChina
| | - Yang Yu
- College of Pharmaceutical SciencesSouthwest UniversityChongqingChina
| |
Collapse
|
20
|
Weng Y, Miao B, Hong D, Zhang M, Wang B, Zhao Q, Wang H. Effects of pharmacist-led interventions on glycaemic control, adherence, disease management and health-related quality of life in patients with type 2 diabetes: a protocol for a network meta-analysis. BMJ Open 2023; 13:e072960. [PMID: 37898486 PMCID: PMC10619031 DOI: 10.1136/bmjopen-2023-072960] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/18/2023] [Accepted: 10/10/2023] [Indexed: 10/30/2023] Open
Abstract
INTRODUCTION The increase in the number of patients with uncontrolled type 2 diabetes mellitus (T2DM) is in need of effective management interventions. However, research to date has been limited to the evaluation of the outcomes of community pharmacists alone. Therefore, the aim of the study protocol is to compare the effects of clinical pharmacist-led intervention strategies for the management of T2DM in the outpatient settings. METHOD AND ANALYSIS The study will collect and analyse data applying standard Cochrane methodological procedures. A search for eligible studies and ongoing trials will be conducted using PubMed, Embase, Medline (via Ovid), EBSCO (via Ovid), Lippincott Williams & Wilkins (LWW) Journals (via Ovid), ProQuest Health and Medical Complete, and ClinicalTrials.gov (clinicaltrials.gov) from database inception to December 2023. Clinical and health outcomes will be measured using both glycaemic control related indicators (eg, glycated haemoglobin, fasting blood glucose, postprandial glucose) and general indicators (eg, adherence, disease management and health-related quality of life). The meta-analysis will conduct pairwise meta-analysis using random effects models and network meta-analysis (NMA) employing the Bayesian hierarchical model. The visualisation and statistical analysis will be carried out using RevMan, R Studio and ADDIS. Additionally, we will evaluate the certainty of the evidence by using Grading of Recommendations Assessment, Development and Evaluation system. ETHICS AND DISSEMINATION There will be no primary data collection from NMA participants, and there is no requirement for formal ethical review. Our aim is to present the results of this NMA in a peer-reviewed scientific journal, at conferences, and in the mainstream media. PROSPERO REGISTRATION NUMBER CRD42022355368.
Collapse
Affiliation(s)
- Yiqing Weng
- Department of Social Medicine of School of Public Health and Department of Pharmacy of the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
| | - Binghui Miao
- Department of Social Medicine of School of Public Health and Department of Pharmacy of the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
| | - Dongsheng Hong
- Department of Clinical Pharmacy, Zhejiang University School of Medicine First Affiliated Hospital, Hangzhou, China
- Zhejiang Provincial Key Laboratory for Drug Evaluation and Clinical Research, Zhejiang University School of Medicine First Affiliated Hospital, Hangzhou, China
| | - Mengdie Zhang
- Department of Social Medicine of School of Public Health and Department of Pharmacy of the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
| | - Beijia Wang
- Department of Social Medicine of School of Public Health and Department of Pharmacy of the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
| | - Qingwei Zhao
- Department of Clinical Pharmacy, Zhejiang University School of Medicine First Affiliated Hospital, Hangzhou, China
- Zhejiang Provincial Key Laboratory for Drug Evaluation and Clinical Research, Zhejiang University School of Medicine First Affiliated Hospital, Hangzhou, China
| | - Hongmei Wang
- Department of Social Medicine of School of Public Health and Department of Pharmacy of the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
| |
Collapse
|
21
|
Song MF, Ma LY, Zhao Q, Shen C, Zhao CY. [Research progress on the mechanism and response strategies of molecular targeted drug resistance in liver cancer]. Zhonghua Gan Zang Bing Za Zhi 2023; 31:1108-1112. [PMID: 38016782 DOI: 10.3760/cma.j.cn501113-20220723-00393] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 11/30/2023]
Abstract
Molecular targeted drugs are one of the treatments for hepatocellular carcinoma (HCC), the primary factor influencing their therapeutic efficacy is drug resistance. Diminished drug intake, greater efflux, improved DNA damage repair capacity, aberrant signal pathways, hypoxia, epithelial-mesenchymal cell transition, and the cellular autophagy system are summarized herein as aspects of the drug resistance mechanism. Simultaneously, effective strategies for addressing drug resistance are elaborated, providing ideas for better clinical treatment of HCC.
Collapse
Affiliation(s)
- M F Song
- Department of Infectious Disease, the Third Hospital of Hebei Medical University, Shijiazhuang 050051, China
| | - L Y Ma
- Department of Infectious Disease, the Third Hospital of Hebei Medical University, Shijiazhuang 050051, China
| | - Q Zhao
- Quality Management and Control Office, the Third Hospital of Hebei Medical University, Shijiazhuang 050051, China
| | - C Shen
- Department of Infectious Disease, the Third Hospital of Hebei Medical University, Shijiazhuang 050051, China
| | - C Y Zhao
- Department of Infectious Disease, the Third Hospital of Hebei Medical University, Shijiazhuang 050051, China
| |
Collapse
|
22
|
Liu F, Wang H, Jiang C, He L, Xiao S, Ye X, Fan C, Wu X, Liu W, Li Y, Wu W, Zhao Q. Dose Painting Radiotherapy Guided by Diffusion-Weighted Magnetic Resonance vs. 18F-FDG-PET/CT in Locoregionally Advanced Nasopharyngeal Carcinoma: A Randomized, Controlled Clinical Trial. Int J Radiat Oncol Biol Phys 2023; 117:S100-S101. [PMID: 37784268 DOI: 10.1016/j.ijrobp.2023.06.054] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) This phase II randomized controlled trial aimed at comparing the efficacy and toxicity of diffusion-weighted magnetic resonance imaging (DWI)-guided dose painting radiotherapy (DP-RT), FDG-PET/CT-guided DP-RT, and conventional MRI-based radiotherapy (RT) in locoregionally advanced nasopharyngeal carcinoma (NPC). MATERIALS/METHODS A total of 330 patients with stage III-IVa NPC disease were randomly assigned in a 1:1:1 ratio to receive induction chemotherapy followed by concurrent chemoradiotherapy by DWI-guided DP-RT (group A, n = 110), FDG-PET/CT-guided DP-RT (group B, n = 110), or conventional MRI-based RT (group C, n = 110). All patients received volumetric modulated arc therapy (VMAT). In group A, subvolume GTVnx-DWI (gross tumor volume of nasopharynx in DWI) was defined as the areas within the GTVnx (gross tumor volume of nasopharynx) with an apparent diffusion coefficient (ADC) below the mean ADC (ADC < mean). In group B, subvolume GTVnx-PET (gross tumor volume of nasopharynx in PET images) was defined within GTVnx as the SUV50%max isocontour. The doses to GTVnx-DWI in group A and GTVnx-PET in group B were escalated to 75.2 Gy/32 fx in patients with T1-2 disease and to 77.55 Gy/33 fx in those with T3-4 disease in 2.35 Gy per fraction. In group C, planning gross tumor volume of nasopharynx (PGTVnx) was irradiated at 70.4 to 72.6 Gy/32 to 33 fx in 2.2 Gy per fraction. This trial is registered with chictr.org.cn (ChiCTR2200057476). RESULTS Group A and B showed significant higher complete response (CR) rates than group C (100%, 100%, and 96.4% for group A, B and C, respectively, p = 0.036). In groups A, B and C, the 1-year local recurrence-free survival (LRFS) rates were 100%, 100%, and 94.5%, respectively (p = 0.002). The 1-year disease-free survival (DFS) rates were 100%, 99.1%, and 92.7%, respectively (p = 0.001). The 1-year distant metastasis-free survival (DMFS) rates were 100%, 99.1%, and 93.6%, respectively (p = 0.004). The 1-year overall survival (OS) rates were 100%, 100%, and 95.4%, respectively (p = 0.006). Group A and B had significantly higher 1-year LRFS, DFS, DMFS, and OS than those in group C. No significant differences were observed in LRFS, DFS, DMFS and OS between group A and B. Group B (PET/CT group) had a higher incidence of grade 3-4 acute ototoxicity (3.6%) than group A (0%) and group C (0%, p = 0.036). No significant differences in other grade 3-4 acute adverse events and late toxic effects were observed among the three groups, and no patient had grade 5 toxicities. Multivariate analysis showed that dose painting (DWI-guided DP-RT and PET/CT-guided DP-RT vs conventional MRI-based RT) was associated with improved LRFS, DFS, DMFS and OS. CONCLUSION Both DWI-guided DP-RT and PET/CT-guided DP-RT plus chemotherapy are associated with improved LRFS, DFS, DMFS and OS compared with conventional MRI-based RT among patients with locoregionally advanced NPC. DWI-guided DP-RT does not increase toxicities, but PET/CT-guided DP-RT has higher incidence of acute ototoxicity.
Collapse
Affiliation(s)
- F Liu
- Hunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China, Changsha, China
| | - H Wang
- Department of Radiation Oncology, Hunan Cancer Hospital & the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China
| | - C Jiang
- Hunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China, Changsha, China
| | - L He
- Hunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China
| | - S Xiao
- Hunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China
| | - X Ye
- Hunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China, Changsha, China
| | - C Fan
- Hunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China, Changsha, China
| | - X Wu
- Hunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China, Changsha, China
| | - W Liu
- Hunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China, Changsha, China
| | - Y Li
- Hunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China
| | - W Wu
- Hunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China, Changsha, China
| | - Q Zhao
- Hunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China, Changsha, China
| |
Collapse
|
23
|
Liu F, Wang H, Jiang C, He L, Xiao S, Yan O, Wu X, Liu W, Ye X, Fan C, Li Y, Zhao Q, Wu W, Tan C. Efficacy and Toxicity of Different Target Volume Delineations of Radiotherapy Based on the Updated RTOG/NRG and EORTC Guidelines in Patients with High Grade Glioma: A Randomized, Controlled Clinical Trial. Int J Radiat Oncol Biol Phys 2023; 117:S84-S85. [PMID: 37784587 DOI: 10.1016/j.ijrobp.2023.06.406] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Postoperative radiotherapy with concomitant and adjuvant temozolomide (TMZ) is the standard of care for newly diagnosed high grade glioma, but the optimal method for target volume delineations for intensity modulated radiation therapy (IMRT) is still unclear. We hypothesized that compared with the EORTC guidelines, IMRT based on the updated RTOG/NRG guidelines was equally effective, without increasing toxicities for patients with high-grade glioma. The purpose of this randomized phase 2 study was to compare the efficacy and toxicity of IMRT based on different target volume delineations (updated RTOG/NRG versus EORTC guidelines) with concomitant and adjuvant TMZ for patients with high grade glioma. MATERIALS/METHODS A total of 302 patients with newly diagnosed high-grade glioma (WHO grade 3-4) were randomly assigned (1:1) to receive postoperative IMRT based on either updated RTOG/NRG guidelines (RTOG/NRG group, n = 151) or EORTC guideline (EORTC group, n = 151), with concomitant and adjuvant TMZ. In the RTOG/NRG group, an initial volume consisting of enhancement, postoperative cavity, plus surrounding edema (or fluid-attenuated inversion recovery [FLAIR] abnormality defined by magnetic resonance imaging [MRI]) and a 2-cm margin received 46 Gy in 23 fractions followed by a boost of 14 Gy in 7 fractions to the area of enhancement plus the cavity and a 2-cm margin. In the EORTC group, a single planning volume was used to deliver 60 Gy in 30 fractions to the area of enhancement and the cavity with a 2-cm margin. The primary end point was overall survival (OS). Secondary end points included progression-free survival (PFS) and toxicities associated with each treatment. RESULTS No statistically significant differences were observed between groups for 1-year OS (71.8% for RTOG/NRG group and 69.9% for EORTC group, respectively; P = 0.759) or 1-year PFS (46.7% for RTOG/NRG group and 43.6% for EORTC group, respectively; P = 0.674). Efficacy did not differ by MGMT methylation status. There were no differences in grade 3-4 toxicities (leukopenia, lymphopenia, neutropenia, thrombocytopenia, fatigue, nausea and vomiting) between the two groups. No grade 5 toxicities were observed in both groups. Multivariate analyses showed that tumor MGMT status (methylated vs unmethylated) and WHO grade (grade 3 vs grade 4) were associated with OS and PFS. However, radiation type (RTOG/NRG group vs EORTC), sex, age, and Karnofsky scale did not significantly influence OS or PFS. CONCLUSION Compared with EORTC guidelines for postoperative radiotherapy, IMRT based on RTOG/NRG guidelines was equally effective, without increasing toxicities for patients with high-grade glioma. This trial is registered with chictr.org.cn, number ChiCTR2100046667.
Collapse
Affiliation(s)
- F Liu
- Hunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China, Changsha, China
| | - H Wang
- Department of Radiation Oncology, Hunan Cancer Hospital & the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China
| | - C Jiang
- Hunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China, Changsha, China
| | - L He
- Hunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China
| | - S Xiao
- Hunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China
| | - O Yan
- Hunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China
| | - X Wu
- Hunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China, Changsha, China
| | - W Liu
- Hunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China, Changsha, China
| | - X Ye
- Hunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China, Changsha, China
| | - C Fan
- Hunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China, Changsha, China
| | - Y Li
- Hunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China
| | - Q Zhao
- Hunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China, Changsha, China
| | - W Wu
- Hunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China, Changsha, China
| | - C Tan
- Hunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China
| |
Collapse
|
24
|
Zhang Y, Zhang Q, Liu Q, Dang H, Gao S, Wang W, Zhou H, Chen Y, Ma L, Wang J, Yang H, Lu B, Yin H, Wu L, Suo S, Zhao Q, Tong H, Jin J. Safety and efficacy of jaktinib (a novel JAK inhibitor) in patients with myelofibrosis who are relapsed or refractory to ruxolitinib: A single-arm, open-label, phase 2, multicenter study. Am J Hematol 2023; 98:1579-1587. [PMID: 37466271 DOI: 10.1002/ajh.27031] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2023] [Revised: 07/03/2023] [Accepted: 07/04/2023] [Indexed: 07/20/2023]
Abstract
Ruxolitinib has demonstrated efficacy in patients with myelofibrosis (MF). However, substantial number of patients may not respond after 3-6 months of treatment or develop resistance over time. In this phase 2 trial, patients with a current diagnosis of intermediate or high-risk MF who either had an inadequate splenic response or spleen regrowth after ruxolitinib treatment were enrolled. All patients received jaktinib 100 mg Bid. The primary endpoint was the proportion of patients with ≥35% reduction in spleen volume (SVR 35) at week 24. The secondary endpoints included change of MF-related symptoms, anemic response, and safety profile. From July 6, 2021, to January 24, 2022, 34 ruxolitinib-refractory or relapsed patients were enrolled, 52.9% (18 of 34) were DIPSS intermediate 2 or high risk. SVR 35 at week 24 was 32.4% (11 of 34, 95% CI 19.1%-49.2%) in all patients and 33.3% (6 of 18, 95% CI 16.3%-56.3%) in the intermediate 2 or high-risk group. A total of 50% (8 of 16) transfusion-independent patients with hemoglobin (HGB) <100 g/L at baseline had HGB elevation ≥20 g/L within 24 weeks. Furthermore, 46.4% (13 of 28) of patients had a ≥ 50% decrease in the total symptom score (TSS 50) at week 24. The most common grade ≥3 treatment-emergent adverse events (TEAEs) were thrombocytopenia (32.4%), anemia (32.4%), and leukocytosis (20.6%). In total, 13 (38.2%) of 34 patients had serious adverse events (SAE), of which drug-related SAEs were found in 5 patients (14.7%). These results indicate that jaktinib can be a promising treatment option for patients with MF who have either become refractory to or relapsed after ruxolitinib treatment.
Collapse
Affiliation(s)
- Yi Zhang
- Department of Hematology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, PR China
- Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China
- Zhejiang Provincial Clinical Research Center for Hematological Disorders, Hangzhou, PR China
- Zhejiang University Cancer Center, Hangzhou, PR China
| | - Qike Zhang
- Department of Hematology, Gansu Provincial Hospital, Lanzhou, PR China
| | - Qingchi Liu
- Department of Hematology, The First Hospital of Hebei Medical University, Shijiazhuang, PR China
| | - Huibing Dang
- Department of Hematology, The First Affiliated Hospital of Nanyang Medical College, Nanyang, PR China
| | - Sujun Gao
- Department of Hematology, The First Hospital of Jilin University, Changchun, PR China
| | - Wei Wang
- Department of Hematology, The Affiliated Hospital of Qingdao University, Qingdao, PR China
| | - Hu Zhou
- Department of Hematology, the Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, PR China
| | - Yuqing Chen
- Department of Hematology, Henan Provincial People's Hospital, Zhengzhou, PR China
| | - Liangming Ma
- Department of Hematology, Shanxi Bethune Hospital, The Third Hospital of Shanxi Medical University, Taiyuan, PR China
| | - Jishi Wang
- Department of Hematology, Affiliated Hospital of Guizhou Medical University, Guiyang, PR China
| | - Haiping Yang
- Department of Hematology, The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, Luoyang, PR China
| | - Binhua Lu
- Suzhou Zelgen Biopharmaceuticals Co, Ltd, Suzhou, PR China
| | - Hewen Yin
- Suzhou Zelgen Biopharmaceuticals Co, Ltd, Suzhou, PR China
| | - Liqing Wu
- Suzhou Zelgen Biopharmaceuticals Co, Ltd, Suzhou, PR China
| | - Shanshan Suo
- Department of Hematology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, PR China
- Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China
- Zhejiang Provincial Clinical Research Center for Hematological Disorders, Hangzhou, PR China
- Zhejiang University Cancer Center, Hangzhou, PR China
| | - Qingwei Zhao
- Department of Clinical pharmacy, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, PR China
| | - Hongyan Tong
- Department of Hematology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, PR China
- Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China
- Zhejiang Provincial Clinical Research Center for Hematological Disorders, Hangzhou, PR China
- Zhejiang University Cancer Center, Hangzhou, PR China
| | - Jie Jin
- Department of Hematology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, PR China
- Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China
- Zhejiang Provincial Clinical Research Center for Hematological Disorders, Hangzhou, PR China
- Zhejiang University Cancer Center, Hangzhou, PR China
| |
Collapse
|
25
|
Zhang Y, Zhou H, Duan M, Gao S, He G, Jing H, Li J, Ma L, Zhu H, Chang C, Du X, Hong M, Li X, Liu Q, Wang W, Xu N, Yang H, Lu B, Yin H, Wu L, Suo S, Zhao Q, Xiao Z, Jin J. Safety and efficacy of jaktinib (a novel JAK inhibitor) in patients with myelofibrosis who are intolerant to ruxolitinib: A single-arm, open-label, phase 2, multicenter study. Am J Hematol 2023; 98:1588-1597. [PMID: 37470365 DOI: 10.1002/ajh.27033] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2023] [Revised: 07/03/2023] [Accepted: 07/04/2023] [Indexed: 07/21/2023]
Abstract
Although ruxolitinib improves splenomegaly and constitutional symptoms in patients with myelofibrosis (MF), a substantial proportion of patients discontinue ruxolitinib because of intolerance. This phase 2 trial investigated the safety and efficacy of jaktinib, a novel JAK inhibitor in patients with ruxolitinib-intolerant MF. The primary endpoint was the proportion of patients with ≥35% reduction in spleen volume (SVR35) at week 24. The secondary endpoints included change of MF-related symptoms, anemic response, and safety profiles. Between December 18, 2019, and November 24, 2021, 51 patients were enrolled, 45 treated with jaktinib 100 mg bid (100 mg bid group) and six received non-100 mg bid doses (non-100 mg bid group). The SVR35 at week 24 in the 100 mg bid group was 43.2% (19/44, 95% CI 29.7%-57.8%). There were 41.9% (13/31) of transfusion-independent patients with hemoglobin (HGB) ≤100 g/L who had HGB elevation ≥20 g/L within 24 weeks. The proportion of patients with a ≥50% decrease in the total symptom score (TSS 50) at week 24 was 61.8% (21/34). The most commonly reported grade ≥3 treatment-emergent adverse events (TEAEs) in the 100 mg bid group were anemia 31.1%, thrombocytopenia 22.2%, and infectious pneumonia 17.8%. A total of 16 (35.6%) in the 100 mg bid group had serious adverse events, and 4 (8.9%) were considered possibly drug related. These results indicate jaktinib can provide a treatment option for patients with MF who are intolerant to ruxolitinib.
Collapse
Affiliation(s)
- Yi Zhang
- Department of Hematology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, People's Republic of China
- Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy, Zhejiang University, Hangzhou, Zhejiang, People's Republic of China
- Zhejiang Provincial Clinical Research Center for Hematological disorders, Hangzhou, People's Republic of China
- Zhejiang University Cancer Center, Hangzhou, People's Republic of China
| | - Hu Zhou
- Department of Hematology, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, People's Republic of China
| | - Minghui Duan
- Department of Hematology, Chinese Academy of Medical Sciences & Peking Union Medical College, Peking Union Medical College Hospital, Beijing, People's Republic of China
| | - Sujun Gao
- Department of Hematology, The First Hospital of Jilin University, Changchun, People's Republic of China
| | - Guangsheng He
- Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Key Laboratory of Hematology of Nanjing Medical University, Collaborative Innovation Center for Cancer Personalize, Jiangsu, People's Republic of China
| | - Hongmei Jing
- Department of Hematology, Peking University Third Hospital, Beijing, People's Republic of China
| | - Junmin Li
- Department of Hematology, Ruijin Hospital, Shanghai Jiaotong University Medical School, Shanghai, People's Republic of China
| | - Liangming Ma
- Department of Hematology, Shanxi Bethune Hospital, The Third Hospital of Shanxi Medical University, Taiyuan, People's Republic of China
| | - Huanling Zhu
- Department of Hematology, West China Hospital, Sichuan University, Chengdu, People's Republic of China
| | - Chunkang Chang
- Department of Hematology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, People's Republic of China
| | - Xin Du
- Department of Hematology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, People's Republic of China
| | - Mei Hong
- Department of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People's Republic of China
| | - Xin Li
- Department of Hematology, The Third Xiangya Hospital, Central South University, Changsha, People's Republic of China
| | - Qingchi Liu
- Department of Hematology, The First Hospital of Hebei Medical University, Shijiazhuang, People's Republic of China
| | - Wei Wang
- Department of Hematology, The Affiliated Hospital of Qingdao University, Qingdao, People's Republic of China
| | - Na Xu
- Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, People's Republic of China
| | - Haiping Yang
- Department of Hematology, The First Affiliated Hospital and College of Clinical Medicine of Henan University of Science and Technology, Luoyang, People's Republic of China
| | - Binhua Lu
- Suzhou Zelgen Biopharmaceuticals Co, Ltd, Suzhou, People's Republic of China
| | - Hewen Yin
- Suzhou Zelgen Biopharmaceuticals Co, Ltd, Suzhou, People's Republic of China
| | - Liqing Wu
- Suzhou Zelgen Biopharmaceuticals Co, Ltd, Suzhou, People's Republic of China
| | - Shanshan Suo
- Department of Hematology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, People's Republic of China
- Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy, Zhejiang University, Hangzhou, Zhejiang, People's Republic of China
- Zhejiang Provincial Clinical Research Center for Hematological disorders, Hangzhou, People's Republic of China
- Zhejiang University Cancer Center, Hangzhou, People's Republic of China
| | - Qingwei Zhao
- Department of Clinical pharmacy, the First Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, People's Republic of China
| | - Zhijian Xiao
- Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, People's Republic of China
| | - Jie Jin
- Department of Hematology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, People's Republic of China
- Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy, Zhejiang University, Hangzhou, Zhejiang, People's Republic of China
- Zhejiang Provincial Clinical Research Center for Hematological disorders, Hangzhou, People's Republic of China
- Zhejiang University Cancer Center, Hangzhou, People's Republic of China
| |
Collapse
|
26
|
Henriques A, Nash S, Barofsky D, Bollen G, Lapierre A, Schwarz S, Sumithrarachchi C, Zhao Q, Villari ACC. Quantification and purification of isotopic contamination at the ReAccelerator of the Facility for Rare Isotope Beams. Rev Sci Instrum 2023; 94:103306. [PMID: 37815423 DOI: 10.1063/5.0165850] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Received: 06/30/2023] [Accepted: 09/19/2023] [Indexed: 10/11/2023]
Abstract
At the ReAccelerator within the Facility for Rare Isotope Beams, a combination of an interchangeable aluminum foil and a silicon detector was developed to quantify isobaric contamination in rare isotope beams. The device is simple to operate and is now used routinely. In this article, we describe the system and show an application of the device to determine the level of contamination of an Si-32 rare isotope beam by stable S-32. In addition, we describe how the new diagnostic device helped confirm an enhancement of the beam purity prior to beam delivery to experiments.
Collapse
Affiliation(s)
- A Henriques
- Facility for Rare Isotope Beams, Michigan State University, East Lansing, Michigan 48824, USA
| | - S Nash
- Facility for Rare Isotope Beams, Michigan State University, East Lansing, Michigan 48824, USA
| | - D Barofsky
- Facility for Rare Isotope Beams, Michigan State University, East Lansing, Michigan 48824, USA
| | - G Bollen
- Facility for Rare Isotope Beams, Michigan State University, East Lansing, Michigan 48824, USA
| | - A Lapierre
- Facility for Rare Isotope Beams, Michigan State University, East Lansing, Michigan 48824, USA
| | - S Schwarz
- Facility for Rare Isotope Beams, Michigan State University, East Lansing, Michigan 48824, USA
| | - C Sumithrarachchi
- Facility for Rare Isotope Beams, Michigan State University, East Lansing, Michigan 48824, USA
| | - Q Zhao
- Facility for Rare Isotope Beams, Michigan State University, East Lansing, Michigan 48824, USA
| | - A C C Villari
- Facility for Rare Isotope Beams, Michigan State University, East Lansing, Michigan 48824, USA
| |
Collapse
|
27
|
Wang Y, Zhao Q, Hamulati X, Tuerxun G, Mutalifu M, Li XM, Yang YN. [Association between sleep quality/physical activity and metabolic syndrome in urban population of Xinjiang]. Zhonghua Xin Xue Guan Bing Za Zhi 2023; 51:963-969. [PMID: 37709713 DOI: 10.3760/cma.j.cn112148-20230324-00173] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 09/16/2023]
Abstract
Objective: To explore the relationship between sleep/physical activity and metabolic syndrome (MS) in urban population of Xinjiang. Methods: This is a prospective, cross-sectional study. From July 2019 to September 2021, a two-stage random sampling method was used to randomly select residents aged 30-74 years from two communities in Urumqi of northern Xinjiang and Korla of southern Xinjiang. General situation questionnaire, Pittsburgh Sleep Quality Index Scale (PSQI) survey, International Physical Activity Questionnaire (IPAQ) survey, physical examination, physiological and biochemical indicators were obtained and analyzed. The dose-response curves of healthy sleep score and physical activity with metabolic syndrome were plotted using restricted cubic spline curves. Multivariate logistic regression model was used to analyze the independent and combined effects of sleep quality and physical activity on MS risk. Results: A total of 10 209 participants were included. The mean age of the subjects was (47.1±9.1) years, and males accounted for 51.3% (5 275/10 209). The prevalence of MS was significantly associated with the healthy sleep score and physical activity. Compared to the subjects with healthy sleep, OR (95%CI) of MS with intermediate, and poor sleep were 1.20(1.06-1.35), 1.23(1.04-1.45), respectively. Compared to the subjects with high physical activity, OR (95%CI) of MS with medium, low physical activity was 1.34(1.15-1.56), 1.42(1.19-1.70), respectively. There was a significant interaction between sleep and physical activity in MS (P for interaction=0.002). Compared to the subjects with high physical activity and healthy sleep, OR (95%CI) of MS with poor sleep and high physical activity was 2.03 (1.24-3.33, P for trend=0.016). Conclusion: Poor sleep quality and lack of physical activity are not only independent risk factors for an increased risk of MS but also have a combined effect with an increased risk of MS.
Collapse
Affiliation(s)
- Y Wang
- Heart Centre, First Affiliated Hospital of Xinjiang Medical University, Urumqi 830054, China
| | - Q Zhao
- Heart Centre, First Affiliated Hospital of Xinjiang Medical University, Urumqi 830054, China
| | - Xieyire Hamulati
- Heart Centre, First Affiliated Hospital of Xinjiang Medical University, Urumqi 830054, China
| | - Gulijiehere Tuerxun
- Heart Centre, First Affiliated Hospital of Xinjiang Medical University, Urumqi 830054, China
| | - Munire Mutalifu
- Heart Centre, First Affiliated Hospital of Xinjiang Medical University, Urumqi 830054, China
| | - X M Li
- Heart Centre, First Affiliated Hospital of Xinjiang Medical University, Urumqi 830054, China
| | - Y N Yang
- Heart Centre, First Affiliated Hospital of Xinjiang Medical University, Urumqi 830054, China
| |
Collapse
|
28
|
Ablikim M, Achasov MN, Adlarson P, Ahmed S, Albrecht M, Aliberti R, Amoroso A, An Q, Bai Y, Bakina O, Ferroli RB, Balossino I, Ban Y, Begzsuren K, Berger N, Bertani M, Bettoni D, Bianchi F, Bloms J, Bortone A, Boyko I, Briere RA, Cai H, Cai X, Calcaterra A, Cao GF, Cao N, Cetin SA, Chang JF, Chang WL, Chelkov G, Chen G, Chen HS, Chen ML, Chen SJ, Chen XR, Chen YB, Chen ZJ, Cheng WS, Cibinetto G, Cossio F, Dai HL, Dai JP, Dai XC, Dbeyssi A, de Boer RE, Dedovich D, Deng ZY, Denig A, Denysenko I, Destefanis M, De Mori F, Ding Y, Dong J, Dong LY, Dong MY, Dong X, Du SX, Fang J, Fang SS, Fang Y, Farinelli R, Fava L, Feldbauer F, Felici G, Feng CQ, Fritsch M, Fu CD, Gao YN, Gao Y, Gao Y, Garzia I, Gersabeck EM, Gilman A, Goetzen K, Gong L, Gong WX, Gradl W, Greco M, Gu LM, Gu MH, Gu S, Gu YT, Guan CY, Guo AQ, Guo LB, Guo RP, Guo YP, Guskov A, Han TT, Hao XQ, Harris FA, He KL, Heinsius FHH, Heinz CH, Heng YK, Herold C, Himmelreich M, Holtmann T, Hou YR, Hou ZL, Hu HM, Hu JF, Hu T, Hu Y, Huang GS, Huang LQ, Huang XT, Huang YP, Hussain T, Imoehl W, Irshad M, Jaeger S, Janchiv S, Ji Q, Ji QP, Ji XB, Ji XL, Jiang XS, Jiao JB, Jiao Z, Jin S, Jin Y, Johansson T, Kalantar-Nayestanaki N, Kang XS, Kappert R, Kavatsyuk M, Ke BC, Keshk IK, Khoukaz A, Kiese P, Kiuchi R, Kliemt R, Kolcu OB, Kopf B, Kuemmel M, Kuessner MK, Kupsc A, Kurth MG, Kühn W, Lane JJ, Larin P, Lavania A, Lavezzi L, Lei ZH, Leithoff H, Lellmann M, Lenz T, Li C, Li CH, Li C, Li DM, Li F, Li G, Li H, Li HB, Li HJ, Li JQ, Li JW, Li K, Li LK, Li L, Li PL, Li PR, Li SY, Li WD, Li WG, Li XH, Li XL, Li ZY, Liang H, Liang H, Liang H, Liang YF, Liang YT, Liao GR, Liao LZ, Libby J, Limphirat A, Liu BJ, Liu CX, Liu D, Liu FH, Liu F, Liu F, Liu HB, Liu HM, Liu H, Liu H, Liu JB, Liu JY, Liu K, Liu KY, Liu L, Liu MH, Liu Q, Liu SB, Liu S, Liu T, Liu WM, Liu X, Liu YB, Liu ZA, Liu ZQ, Lou XC, Lu FX, Lu HJ, Lu JD, Lu JG, Lu XL, Lu Y, Lu YP, Luo CL, Luo MX, Luo T, Luo XL, Lusso S, Lyu XR, Ma FC, Ma HL, Ma LL, Ma MM, Ma QM, Ma RQ, Ma RT, Ma XX, Ma XY, Maas FE, Maggiora M, Maldaner S, Malde S, Malik QA, Mangoni A, Mao YJ, Mao ZP, Marcello S, Meng ZX, Messchendorp JG, Mezzadri G, Min TJ, Mitchell RE, Mo XH, Muchnoi NY, Muramatsu H, Nakhoul S, Nefedov Y, Nerling F, Nikolaev IB, Ning Z, Nisar S, Olsen SL, Ouyang Q, Pacetti S, Pan X, Pan Y, Pathak A, Patteri P, Pelizaeus M, Peng HP, Peters K, Ping JL, Ping RG, Pitka A, Poling R, Prasad V, Qi H, Qi HR, Qi M, Qi TY, Qian S, Qian WB, Qiao CF, Qin LQ, Qin XP, Qin XS, Qin ZH, Qiu JF, Qu SQ, Qu SQ, Ravindran K, Redmer CF, Rivetti A, Rodin V, Rolo M, Rong G, Rosner C, Sarantsev A, Schelhaas Y, Schnier C, Schoenning K, Scodeggio M, Shan DC, Shan W, Shan XY, Shao M, Shen CP, Shen PX, Shen XY, Shi HC, Shi RS, Shi X, Shi XD, Song WM, Song YX, Sosio S, Spataro S, Su KX, Sun GX, Sun JF, Sun L, Sun SS, Sun T, Sun WY, Sun YJ, Sun YK, Sun YZ, Sun ZT, Tan YH, Tan YX, Tang CJ, Tang GY, Tang J, Teng JX, Thoren V, Uman I, Wang B, Wang BL, Wang CW, Wang DY, Wang HP, Wang K, Wang LL, Wang M, Wang M, Wang WH, Wang WP, Wang X, Wang XF, Wang XL, Wang Y, Wang YD, Wang YF, Wang YQ, Wang Z, Wang ZY, Wang Z, Wang Z, Wei DH, Weidenkaff P, Weidner F, Wen SP, White DJ, Wiedner UW, Wilkinson G, Wolke M, Wollenberg L, Wu JF, Wu LH, Wu LJ, Wu X, Wu Z, Xia L, Xiao H, Xiao SY, Xiao ZJ, Xie XH, Xie YG, Xie YH, Xing TY, Xu GF, Xu JJ, Xu QJ, Xu W, Xu XP, Xu YC, Yan F, Yan L, Yan WB, Yan WC, Yan X, Yang HJ, Yang HX, Yang L, Yang SL, Yang YH, Yang Y, Ye M, Ye MH, Yin JH, You ZY, Yu BX, Yu CX, Yu G, Yu JS, Yu T, Yuan CZ, Yuan L, Yuan W, Yuan Y, Yuan ZY, Yue CX, Zafar AA, Zeng Y, Zhang BX, Zhang GY, Zhang H, Zhang HH, Zhang HH, Zhang HY, Zhang JJ, Zhang JQ, Zhang JW, Zhang JY, Zhang JZ, Zhang J, Zhang J, Zhang L, Zhang SF, Zhang XD, Zhang XY, Zhang Y, Zhang YT, Zhang YH, Zhang Y, Zhang Y, Zhang ZY, Zhao G, Zhao J, Zhao JY, Zhao JZ, Zhao L, Zhao L, Zhao MG, Zhao Q, Zhao SJ, Zhao YB, Zhao YX, Zhao ZG, Zhemchugov A, Zheng B, Zheng JP, Zheng YH, Zhong B, Zhong C, Zhou LP, Zhou Q, Zhou X, Zhou XK, Zhou XR, Zhu AN, Zhu J, Zhu K, Zhu KJ, Zhu SH, Zhu WJ, Zhu WJ, Zhu YC, Zhu ZA, Zou BS, Zou JH. Search for Λ[over ¯]-Λ Baryon-Number-Violating Oscillations in the Decay J/ψ→pK^{-}Λ[over ¯]+c.c. Phys Rev Lett 2023; 131:121801. [PMID: 37802947 DOI: 10.1103/physrevlett.131.121801] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/08/2023] [Revised: 08/14/2023] [Accepted: 08/29/2023] [Indexed: 10/08/2023]
Abstract
We report on the first search for Λ[over ¯]-Λ oscillations in the decay J/ψ→pK^{-}Λ[over ¯]+c.c. by analyzing 1.31×10^{9} J/ψ events accumulated with the BESIII detector at the BEPCII collider. The J/ψ events are produced using e^{+}e^{-} collisions at a center of mass energy sqrt[s]=3.097 GeV. No evidence for hyperon oscillations is observed. The upper limit for the oscillation rate of Λ[over ¯] to Λ hyperons is determined to be P(Λ)=[B(J/ψ→pK^{-}Λ+c.c.)/B(J/ψ→pK^{-}Λ[over ¯]+c.c.)]<4.4×10^{-6} corresponding to an oscillation parameter δm_{ΛΛ[over ¯]} of less than 3.8×10^{-18} GeV at the 90% confidence level.
Collapse
Affiliation(s)
- M Ablikim
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - M N Achasov
- Budker Institute of Nuclear Physics SB RAS (BINP), Novosibirsk 630090, Russia
| | - P Adlarson
- Uppsala University, Box 516, SE-75120 Uppsala, Sweden
| | - S Ahmed
- Helmholtz Institute Mainz, Staudinger Weg 18, D-55099 Mainz, Germany
| | - M Albrecht
- Bochum Ruhr-University, D-44780 Bochum, Germany
| | - R Aliberti
- Johannes Gutenberg University of Mainz, Johann-Joachim-Becher-Weg 45, D-55099 Mainz, Germany
| | - A Amoroso
- University of Turin and INFN, University of Turin, I-10125, Turin, Italy
- INFN, I-10125, Turin, Italy
| | - Q An
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Science and Technology of China, Hefei 230026, People's Republic of China
| | - Y Bai
- Southeast University, Nanjing 211100, People's Republic of China
| | - O Bakina
- Joint Institute for Nuclear Research, 141980 Dubna, Moscow region, Russia
| | - R Baldini Ferroli
- INFN Laboratori Nazionali di Frascati, INFN Laboratori Nazionali di Frascati, I-00044, Frascati, Italy
| | - I Balossino
- INFN Sezione di Ferrara, INFN Sezione di Ferrara, I-44122, Ferrara, Italy
| | - Y Ban
- Peking University, Beijing 100871, People's Republic of China
| | - K Begzsuren
- Institute of Physics and Technology, Peace Avenue 54B, Ulaanbaatar 13330, Mongolia
| | - N Berger
- Johannes Gutenberg University of Mainz, Johann-Joachim-Becher-Weg 45, D-55099 Mainz, Germany
| | - M Bertani
- INFN Laboratori Nazionali di Frascati, INFN Laboratori Nazionali di Frascati, I-00044, Frascati, Italy
| | - D Bettoni
- INFN Sezione di Ferrara, INFN Sezione di Ferrara, I-44122, Ferrara, Italy
| | - F Bianchi
- University of Turin and INFN, University of Turin, I-10125, Turin, Italy
- INFN, I-10125, Turin, Italy
| | - J Bloms
- University of Muenster, Wilhelm-Klemm-Strasse 9, 48149 Muenster, Germany
| | - A Bortone
- University of Turin and INFN, University of Turin, I-10125, Turin, Italy
- INFN, I-10125, Turin, Italy
| | - I Boyko
- Joint Institute for Nuclear Research, 141980 Dubna, Moscow region, Russia
| | - R A Briere
- Carnegie Mellon University, Pittsburgh, Pennsylvania 15213, USA
| | - H Cai
- Wuhan University, Wuhan 430072, People's Republic of China
| | - X Cai
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
| | - A Calcaterra
- INFN Laboratori Nazionali di Frascati, INFN Laboratori Nazionali di Frascati, I-00044, Frascati, Italy
| | - G F Cao
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - N Cao
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - S A Cetin
- Turkish Accelerator Center Particle Factory Group, Istinye University, 34010, Istanbul, Turkey
| | - J F Chang
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
| | - W L Chang
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - G Chelkov
- Joint Institute for Nuclear Research, 141980 Dubna, Moscow region, Russia
| | - G Chen
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - H S Chen
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - M L Chen
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - S J Chen
- Nanjing University, Nanjing 210093, People's Republic of China
| | - X R Chen
- Institute of Modern Physics, Lanzhou 730000, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - Y B Chen
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
| | - Z J Chen
- Hunan University, Changsha 410082, People's Republic of China
| | | | - G Cibinetto
- INFN Sezione di Ferrara, INFN Sezione di Ferrara, I-44122, Ferrara, Italy
| | | | - H L Dai
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
| | - J P Dai
- Shanghai Jiao Tong University, Shanghai 200240, People's Republic of China
| | - X C Dai
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - A Dbeyssi
- Helmholtz Institute Mainz, Staudinger Weg 18, D-55099 Mainz, Germany
| | - R E de Boer
- Bochum Ruhr-University, D-44780 Bochum, Germany
| | - D Dedovich
- Joint Institute for Nuclear Research, 141980 Dubna, Moscow region, Russia
| | - Z Y Deng
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - A Denig
- Johannes Gutenberg University of Mainz, Johann-Joachim-Becher-Weg 45, D-55099 Mainz, Germany
| | - I Denysenko
- Joint Institute for Nuclear Research, 141980 Dubna, Moscow region, Russia
| | - M Destefanis
- University of Turin and INFN, University of Turin, I-10125, Turin, Italy
- INFN, I-10125, Turin, Italy
| | - F De Mori
- University of Turin and INFN, University of Turin, I-10125, Turin, Italy
- INFN, I-10125, Turin, Italy
| | - Y Ding
- Liaoning University, Shenyang 110036, People's Republic of China
| | - J Dong
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
| | - L Y Dong
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - M Y Dong
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - X Dong
- Wuhan University, Wuhan 430072, People's Republic of China
| | - S X Du
- Zhengzhou University, Zhengzhou 450001, People's Republic of China
| | - J Fang
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
| | - S S Fang
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - Y Fang
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - R Farinelli
- INFN Sezione di Ferrara, INFN Sezione di Ferrara, I-44122, Ferrara, Italy
| | - L Fava
- University of Eastern Piedmont, I-15121, Alessandria, Italy
- INFN, I-10125, Turin, Italy
| | - F Feldbauer
- Bochum Ruhr-University, D-44780 Bochum, Germany
| | - G Felici
- INFN Laboratori Nazionali di Frascati, INFN Laboratori Nazionali di Frascati, I-00044, Frascati, Italy
| | - C Q Feng
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Science and Technology of China, Hefei 230026, People's Republic of China
| | - M Fritsch
- Bochum Ruhr-University, D-44780 Bochum, Germany
| | - C D Fu
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - Y N Gao
- Peking University, Beijing 100871, People's Republic of China
| | - Ya Gao
- University of South China, Hengyang 421001, People's Republic of China
| | - Yang Gao
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Science and Technology of China, Hefei 230026, People's Republic of China
| | - I Garzia
- INFN Sezione di Ferrara, INFN Sezione di Ferrara, I-44122, Ferrara, Italy
- University of Ferrara, I-44122, Ferrara, Italy
| | - E M Gersabeck
- University of Manchester, Oxford Road, Manchester, M13 9PL, United Kingdom
| | - A Gilman
- University of Minnesota, Minneapolis, Minnesota 55455, USA
| | - K Goetzen
- GSI Helmholtzcentre for Heavy Ion Research GmbH, D-64291 Darmstadt, Germany
| | - L Gong
- Liaoning University, Shenyang 110036, People's Republic of China
| | - W X Gong
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
| | - W Gradl
- Johannes Gutenberg University of Mainz, Johann-Joachim-Becher-Weg 45, D-55099 Mainz, Germany
| | - M Greco
- University of Turin and INFN, University of Turin, I-10125, Turin, Italy
- INFN, I-10125, Turin, Italy
| | - L M Gu
- Nanjing University, Nanjing 210093, People's Republic of China
| | - M H Gu
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
| | - S Gu
- Beihang University, Beijing 100191, People's Republic of China
| | - Y T Gu
- Guangxi University, Nanning 530004, People's Republic of China
| | - C Y Guan
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - A Q Guo
- Indiana University, Bloomington, Indiana 47405, USA
| | - L B Guo
- Nanjing Normal University, Nanjing 210023, People's Republic of China
| | - R P Guo
- Shandong Normal University, Jinan 250014, People's Republic of China
| | - Y P Guo
- Fudan University, Shanghai 200433, People's Republic of China
| | - A Guskov
- Joint Institute for Nuclear Research, 141980 Dubna, Moscow region, Russia
| | - T T Han
- Shandong University, Jinan 250100, People's Republic of China
| | - X Q Hao
- Henan Normal University, Xinxiang 453007, People's Republic of China
| | - F A Harris
- University of Hawaii, Honolulu, Hawaii 96822, USA
| | - K L He
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | | | - C H Heinz
- Johannes Gutenberg University of Mainz, Johann-Joachim-Becher-Weg 45, D-55099 Mainz, Germany
| | - Y K Heng
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - C Herold
- Suranaree University of Technology, University Avenue 111, Nakhon Ratchasima 30000, Thailand
| | - M Himmelreich
- GSI Helmholtzcentre for Heavy Ion Research GmbH, D-64291 Darmstadt, Germany
| | - T Holtmann
- Bochum Ruhr-University, D-44780 Bochum, Germany
| | - Y R Hou
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - Z L Hou
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - H M Hu
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - J F Hu
- South China Normal University, Guangzhou 510006, People's Republic of China
| | - T Hu
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - Y Hu
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - G S Huang
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Science and Technology of China, Hefei 230026, People's Republic of China
| | - L Q Huang
- University of South China, Hengyang 421001, People's Republic of China
| | - X T Huang
- Shandong University, Jinan 250100, People's Republic of China
| | - Y P Huang
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - T Hussain
- University of the Punjab, Lahore-54590, Pakistan
| | - W Imoehl
- Indiana University, Bloomington, Indiana 47405, USA
| | - M Irshad
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Science and Technology of China, Hefei 230026, People's Republic of China
| | - S Jaeger
- Bochum Ruhr-University, D-44780 Bochum, Germany
| | - S Janchiv
- Institute of Physics and Technology, Peace Avenue 54B, Ulaanbaatar 13330, Mongolia
| | - Q Ji
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - Q P Ji
- Henan Normal University, Xinxiang 453007, People's Republic of China
| | - X B Ji
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - X L Ji
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
| | - X S Jiang
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - J B Jiao
- Shandong University, Jinan 250100, People's Republic of China
| | - Z Jiao
- Huangshan College, Huangshan 245000, People's Republic of China
| | - S Jin
- Nanjing University, Nanjing 210093, People's Republic of China
| | - Y Jin
- University of Jinan, Jinan 250022, People's Republic of China
| | - T Johansson
- Uppsala University, Box 516, SE-75120 Uppsala, Sweden
| | | | - X S Kang
- Liaoning University, Shenyang 110036, People's Republic of China
| | - R Kappert
- University of Groningen, NL-9747 AA Groningen, The Netherlands
| | - M Kavatsyuk
- University of Groningen, NL-9747 AA Groningen, The Netherlands
| | - B C Ke
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- Shanxi Normal University, Linfen 041004, People's Republic of China
| | - I K Keshk
- Bochum Ruhr-University, D-44780 Bochum, Germany
| | - A Khoukaz
- University of Muenster, Wilhelm-Klemm-Strasse 9, 48149 Muenster, Germany
| | - P Kiese
- Johannes Gutenberg University of Mainz, Johann-Joachim-Becher-Weg 45, D-55099 Mainz, Germany
| | - R Kiuchi
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - R Kliemt
- GSI Helmholtzcentre for Heavy Ion Research GmbH, D-64291 Darmstadt, Germany
| | - O B Kolcu
- Turkish Accelerator Center Particle Factory Group, Istinye University, 34010, Istanbul, Turkey
| | - B Kopf
- Bochum Ruhr-University, D-44780 Bochum, Germany
| | - M Kuemmel
- Bochum Ruhr-University, D-44780 Bochum, Germany
| | | | - A Kupsc
- Uppsala University, Box 516, SE-75120 Uppsala, Sweden
| | - M G Kurth
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - W Kühn
- Justus-Liebig-Universitaet Giessen, II. Physikalisches Institut, Heinrich-Buff-Ring 16, D-35392 Giessen, Germany
| | - J J Lane
- University of Manchester, Oxford Road, Manchester, M13 9PL, United Kingdom
| | - P Larin
- Helmholtz Institute Mainz, Staudinger Weg 18, D-55099 Mainz, Germany
| | - A Lavania
- Indian Institute of Technology Madras, Chennai 600036, India
| | - L Lavezzi
- University of Turin and INFN, University of Turin, I-10125, Turin, Italy
- INFN, I-10125, Turin, Italy
| | - Z H Lei
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Science and Technology of China, Hefei 230026, People's Republic of China
| | - H Leithoff
- Johannes Gutenberg University of Mainz, Johann-Joachim-Becher-Weg 45, D-55099 Mainz, Germany
| | - M Lellmann
- Johannes Gutenberg University of Mainz, Johann-Joachim-Becher-Weg 45, D-55099 Mainz, Germany
| | - T Lenz
- Johannes Gutenberg University of Mainz, Johann-Joachim-Becher-Weg 45, D-55099 Mainz, Germany
| | - C Li
- Qufu Normal University, Qufu 273165, People's Republic of China
| | - C H Li
- Liaoning Normal University, Dalian 116029, People's Republic of China
| | - Cheng Li
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Science and Technology of China, Hefei 230026, People's Republic of China
| | - D M Li
- Zhengzhou University, Zhengzhou 450001, People's Republic of China
| | - F Li
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
| | - G Li
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - H Li
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Science and Technology of China, Hefei 230026, People's Republic of China
| | - H B Li
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - H J Li
- Fudan University, Shanghai 200433, People's Republic of China
| | - J Q Li
- Bochum Ruhr-University, D-44780 Bochum, Germany
| | - J W Li
- Shandong University, Jinan 250100, People's Republic of China
| | - Ke Li
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - L K Li
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - Lei Li
- Beijing Institute of Petrochemical Technology, Beijing 102617, People's Republic of China
| | - P L Li
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Science and Technology of China, Hefei 230026, People's Republic of China
| | - P R Li
- Lanzhou University, Lanzhou 730000, People's Republic of China
| | - S Y Li
- Tsinghua University, Beijing 100084, People's Republic of China
| | - W D Li
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - W G Li
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - X H Li
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Science and Technology of China, Hefei 230026, People's Republic of China
| | - X L Li
- Shandong University, Jinan 250100, People's Republic of China
| | - Z Y Li
- Sun Yat-Sen University, Guangzhou 510275, People's Republic of China
| | - H Liang
- Jilin University, Changchun 130012, People's Republic of China
| | - H Liang
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - H Liang
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Science and Technology of China, Hefei 230026, People's Republic of China
| | - Y F Liang
- Sichuan University, Chengdu 610064, People's Republic of China
| | - Y T Liang
- Institute of Modern Physics, Lanzhou 730000, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - G R Liao
- Guangxi Normal University, Guilin 541004, People's Republic of China
| | - L Z Liao
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - J Libby
- Indian Institute of Technology Madras, Chennai 600036, India
| | - A Limphirat
- Suranaree University of Technology, University Avenue 111, Nakhon Ratchasima 30000, Thailand
| | - B J Liu
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - C X Liu
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - D Liu
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Science and Technology of China, Hefei 230026, People's Republic of China
| | - F H Liu
- Shanxi University, Taiyuan 030006, People's Republic of China
| | - Fang Liu
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - Feng Liu
- Central China Normal University, Wuhan 430079, People's Republic of China
| | - H B Liu
- Guangxi University, Nanning 530004, People's Republic of China
| | - H M Liu
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - Huanhuan Liu
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - Huihui Liu
- Henan University of Science and Technology, Luoyang 471003, People's Republic of China
| | - J B Liu
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Science and Technology of China, Hefei 230026, People's Republic of China
| | - J Y Liu
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - K Liu
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - K Y Liu
- Liaoning University, Shenyang 110036, People's Republic of China
| | - L Liu
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Science and Technology of China, Hefei 230026, People's Republic of China
| | - M H Liu
- Fudan University, Shanghai 200433, People's Republic of China
| | - Q Liu
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - S B Liu
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Science and Technology of China, Hefei 230026, People's Republic of China
| | - Shuai Liu
- Soochow University, Suzhou 215006, People's Republic of China
| | - T Liu
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - W M Liu
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Science and Technology of China, Hefei 230026, People's Republic of China
| | - X Liu
- Lanzhou University, Lanzhou 730000, People's Republic of China
| | - Y B Liu
- Nankai University, Tianjin 300071, People's Republic of China
| | - Z A Liu
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - Z Q Liu
- Shandong University, Jinan 250100, People's Republic of China
| | - X C Lou
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - F X Lu
- Henan Normal University, Xinxiang 453007, People's Republic of China
| | - H J Lu
- Huangshan College, Huangshan 245000, People's Republic of China
| | - J D Lu
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - J G Lu
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
| | - X L Lu
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - Y Lu
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - Y P Lu
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
| | - C L Luo
- Nanjing Normal University, Nanjing 210023, People's Republic of China
| | - M X Luo
- Zhejiang University, Hangzhou 310027, People's Republic of China
| | - T Luo
- Fudan University, Shanghai 200433, People's Republic of China
| | - X L Luo
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
| | | | - X R Lyu
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - F C Ma
- Liaoning University, Shenyang 110036, People's Republic of China
| | - H L Ma
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - L L Ma
- Shandong University, Jinan 250100, People's Republic of China
| | - M M Ma
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - Q M Ma
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - R Q Ma
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - R T Ma
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - X X Ma
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - X Y Ma
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
| | - F E Maas
- Helmholtz Institute Mainz, Staudinger Weg 18, D-55099 Mainz, Germany
| | - M Maggiora
- University of Turin and INFN, University of Turin, I-10125, Turin, Italy
- INFN, I-10125, Turin, Italy
| | - S Maldaner
- Bochum Ruhr-University, D-44780 Bochum, Germany
| | - S Malde
- University of Oxford, Keble Road, Oxford OX13RH, United Kingdom
| | - Q A Malik
- University of the Punjab, Lahore-54590, Pakistan
| | - A Mangoni
- INFN Sezione di Perugia, I-06100, Perugia, Italy
| | - Y J Mao
- Peking University, Beijing 100871, People's Republic of China
| | - Z P Mao
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - S Marcello
- University of Turin and INFN, University of Turin, I-10125, Turin, Italy
- INFN, I-10125, Turin, Italy
| | - Z X Meng
- University of Jinan, Jinan 250022, People's Republic of China
| | - J G Messchendorp
- GSI Helmholtzcentre for Heavy Ion Research GmbH, D-64291 Darmstadt, Germany
- University of Groningen, NL-9747 AA Groningen, The Netherlands
| | - G Mezzadri
- INFN Sezione di Ferrara, INFN Sezione di Ferrara, I-44122, Ferrara, Italy
| | - T J Min
- Nanjing University, Nanjing 210093, People's Republic of China
| | - R E Mitchell
- Indiana University, Bloomington, Indiana 47405, USA
| | - X H Mo
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - N Yu Muchnoi
- Budker Institute of Nuclear Physics SB RAS (BINP), Novosibirsk 630090, Russia
| | - H Muramatsu
- University of Minnesota, Minneapolis, Minnesota 55455, USA
| | - S Nakhoul
- GSI Helmholtzcentre for Heavy Ion Research GmbH, D-64291 Darmstadt, Germany
| | - Y Nefedov
- Joint Institute for Nuclear Research, 141980 Dubna, Moscow region, Russia
| | - F Nerling
- GSI Helmholtzcentre for Heavy Ion Research GmbH, D-64291 Darmstadt, Germany
| | - I B Nikolaev
- Budker Institute of Nuclear Physics SB RAS (BINP), Novosibirsk 630090, Russia
| | - Z Ning
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
| | - S Nisar
- COMSATS University Islamabad, Lahore Campus, Defence Road, Off Raiwind Road, 54000 Lahore, Pakistan
| | - S L Olsen
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - Q Ouyang
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - S Pacetti
- INFN Sezione di Perugia, I-06100, Perugia, Italy
- University of Perugia, I-06100, Perugia, Italy
| | - X Pan
- Fudan University, Shanghai 200433, People's Republic of China
| | - Y Pan
- University of Manchester, Oxford Road, Manchester, M13 9PL, United Kingdom
| | - A Pathak
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - P Patteri
- INFN Laboratori Nazionali di Frascati, INFN Laboratori Nazionali di Frascati, I-00044, Frascati, Italy
| | - M Pelizaeus
- Bochum Ruhr-University, D-44780 Bochum, Germany
| | - H P Peng
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Science and Technology of China, Hefei 230026, People's Republic of China
| | - K Peters
- GSI Helmholtzcentre for Heavy Ion Research GmbH, D-64291 Darmstadt, Germany
| | - J L Ping
- Nanjing Normal University, Nanjing 210023, People's Republic of China
| | - R G Ping
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - A Pitka
- Bochum Ruhr-University, D-44780 Bochum, Germany
| | - R Poling
- University of Minnesota, Minneapolis, Minnesota 55455, USA
| | - V Prasad
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Science and Technology of China, Hefei 230026, People's Republic of China
| | - H Qi
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Science and Technology of China, Hefei 230026, People's Republic of China
| | - H R Qi
- Tsinghua University, Beijing 100084, People's Republic of China
| | - M Qi
- Nanjing University, Nanjing 210093, People's Republic of China
| | - T Y Qi
- Beihang University, Beijing 100191, People's Republic of China
| | - S Qian
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
| | - W B Qian
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - C F Qiao
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - L Q Qin
- Guangxi Normal University, Guilin 541004, People's Republic of China
| | - X P Qin
- Fudan University, Shanghai 200433, People's Republic of China
| | - X S Qin
- Shandong University, Jinan 250100, People's Republic of China
| | - Z H Qin
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
| | - J F Qiu
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - S Q Qu
- Nankai University, Tianjin 300071, People's Republic of China
| | - S Q Qu
- Tsinghua University, Beijing 100084, People's Republic of China
| | - K Ravindran
- Indian Institute of Technology Madras, Chennai 600036, India
| | - C F Redmer
- Johannes Gutenberg University of Mainz, Johann-Joachim-Becher-Weg 45, D-55099 Mainz, Germany
| | | | - V Rodin
- University of Groningen, NL-9747 AA Groningen, The Netherlands
| | - M Rolo
- INFN, I-10125, Turin, Italy
| | - G Rong
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - Ch Rosner
- Helmholtz Institute Mainz, Staudinger Weg 18, D-55099 Mainz, Germany
| | - A Sarantsev
- Joint Institute for Nuclear Research, 141980 Dubna, Moscow region, Russia
| | - Y Schelhaas
- Johannes Gutenberg University of Mainz, Johann-Joachim-Becher-Weg 45, D-55099 Mainz, Germany
| | - C Schnier
- Bochum Ruhr-University, D-44780 Bochum, Germany
| | - K Schoenning
- Uppsala University, Box 516, SE-75120 Uppsala, Sweden
| | - M Scodeggio
- INFN Sezione di Ferrara, INFN Sezione di Ferrara, I-44122, Ferrara, Italy
- University of Ferrara, I-44122, Ferrara, Italy
| | - D C Shan
- Soochow University, Suzhou 215006, People's Republic of China
| | - W Shan
- Hunan Normal University, Changsha 410081, People's Republic of China
| | - X Y Shan
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Science and Technology of China, Hefei 230026, People's Republic of China
| | - M Shao
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Science and Technology of China, Hefei 230026, People's Republic of China
| | - C P Shen
- Fudan University, Shanghai 200433, People's Republic of China
| | - P X Shen
- Nankai University, Tianjin 300071, People's Republic of China
| | - X Y Shen
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - H C Shi
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Science and Technology of China, Hefei 230026, People's Republic of China
| | - R S Shi
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - X Shi
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
| | - X D Shi
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Science and Technology of China, Hefei 230026, People's Republic of China
| | - W M Song
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- Jilin University, Changchun 130012, People's Republic of China
| | - Y X Song
- Peking University, Beijing 100871, People's Republic of China
| | - S Sosio
- University of Turin and INFN, University of Turin, I-10125, Turin, Italy
- INFN, I-10125, Turin, Italy
| | - S Spataro
- University of Turin and INFN, University of Turin, I-10125, Turin, Italy
- INFN, I-10125, Turin, Italy
| | - K X Su
- Wuhan University, Wuhan 430072, People's Republic of China
| | - G X Sun
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - J F Sun
- Henan Normal University, Xinxiang 453007, People's Republic of China
| | - L Sun
- Wuhan University, Wuhan 430072, People's Republic of China
| | - S S Sun
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - T Sun
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - W Y Sun
- Nanjing Normal University, Nanjing 210023, People's Republic of China
| | - Y J Sun
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Science and Technology of China, Hefei 230026, People's Republic of China
| | - Y K Sun
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Science and Technology of China, Hefei 230026, People's Republic of China
| | - Y Z Sun
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - Z T Sun
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - Y H Tan
- Wuhan University, Wuhan 430072, People's Republic of China
| | - Y X Tan
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Science and Technology of China, Hefei 230026, People's Republic of China
| | - C J Tang
- Sichuan University, Chengdu 610064, People's Republic of China
| | - G Y Tang
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - J Tang
- Sun Yat-Sen University, Guangzhou 510275, People's Republic of China
| | - J X Teng
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Science and Technology of China, Hefei 230026, People's Republic of China
| | - V Thoren
- Uppsala University, Box 516, SE-75120 Uppsala, Sweden
| | - I Uman
- Near East University, Nicosia, North Cyprus, 99138, Mersin 10, Turkey
| | - B Wang
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - B L Wang
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - C W Wang
- Nanjing University, Nanjing 210093, People's Republic of China
| | - D Y Wang
- Peking University, Beijing 100871, People's Republic of China
| | - H P Wang
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - K Wang
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
| | - L L Wang
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - M Wang
- Shandong University, Jinan 250100, People's Republic of China
| | - Meng Wang
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - W H Wang
- Wuhan University, Wuhan 430072, People's Republic of China
| | - W P Wang
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Science and Technology of China, Hefei 230026, People's Republic of China
| | - X Wang
- Peking University, Beijing 100871, People's Republic of China
| | - X F Wang
- Lanzhou University, Lanzhou 730000, People's Republic of China
| | - X L Wang
- Fudan University, Shanghai 200433, People's Republic of China
| | - Y Wang
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Science and Technology of China, Hefei 230026, People's Republic of China
| | - Y D Wang
- North China Electric Power University, Beijing 102206, People's Republic of China
| | - Y F Wang
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - Y Q Wang
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - Z Wang
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
| | - Z Y Wang
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - Ziyi Wang
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - Zongyuan Wang
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - D H Wei
- Guangxi Normal University, Guilin 541004, People's Republic of China
| | - P Weidenkaff
- Johannes Gutenberg University of Mainz, Johann-Joachim-Becher-Weg 45, D-55099 Mainz, Germany
| | - F Weidner
- University of Muenster, Wilhelm-Klemm-Strasse 9, 48149 Muenster, Germany
| | - S P Wen
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - D J White
- University of Manchester, Oxford Road, Manchester, M13 9PL, United Kingdom
| | - U W Wiedner
- Bochum Ruhr-University, D-44780 Bochum, Germany
| | - G Wilkinson
- University of Oxford, Keble Road, Oxford OX13RH, United Kingdom
| | - M Wolke
- Uppsala University, Box 516, SE-75120 Uppsala, Sweden
| | | | - J F Wu
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - L H Wu
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - L J Wu
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - X Wu
- Fudan University, Shanghai 200433, People's Republic of China
| | - Z Wu
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
| | - L Xia
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Science and Technology of China, Hefei 230026, People's Republic of China
| | - H Xiao
- Fudan University, Shanghai 200433, People's Republic of China
| | - S Y Xiao
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - Z J Xiao
- Nanjing Normal University, Nanjing 210023, People's Republic of China
| | - X H Xie
- Peking University, Beijing 100871, People's Republic of China
| | - Y G Xie
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
| | - Y H Xie
- Central China Normal University, Wuhan 430079, People's Republic of China
| | - T Y Xing
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - G F Xu
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - J J Xu
- Nanjing University, Nanjing 210093, People's Republic of China
| | - Q J Xu
- Hangzhou Normal University, Hangzhou 310036, People's Republic of China
| | - W Xu
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - X P Xu
- Soochow University, Suzhou 215006, People's Republic of China
| | - Y C Xu
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - F Yan
- Fudan University, Shanghai 200433, People's Republic of China
| | - L Yan
- Fudan University, Shanghai 200433, People's Republic of China
| | - W B Yan
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Science and Technology of China, Hefei 230026, People's Republic of China
| | - W C Yan
- Zhengzhou University, Zhengzhou 450001, People's Republic of China
| | - Xu Yan
- Soochow University, Suzhou 215006, People's Republic of China
| | - H J Yang
- Shanghai Jiao Tong University, Shanghai 200240, People's Republic of China
| | - H X Yang
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - L Yang
- Shanxi Normal University, Linfen 041004, People's Republic of China
| | - S L Yang
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - Y H Yang
- Nanjing University, Nanjing 210093, People's Republic of China
| | - Yifan Yang
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - M Ye
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
| | - M H Ye
- China Center of Advanced Science and Technology, Beijing 100190, People's Republic of China
| | - J H Yin
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - Z Y You
- Sun Yat-Sen University, Guangzhou 510275, People's Republic of China
| | - B X Yu
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - C X Yu
- Nankai University, Tianjin 300071, People's Republic of China
| | - G Yu
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - J S Yu
- Hunan University, Changsha 410082, People's Republic of China
| | - T Yu
- University of South China, Hengyang 421001, People's Republic of China
| | - C Z Yuan
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - L Yuan
- Beihang University, Beijing 100191, People's Republic of China
| | - W Yuan
- University of Turin and INFN, University of Turin, I-10125, Turin, Italy
- INFN, I-10125, Turin, Italy
| | - Y Yuan
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - Z Y Yuan
- Sun Yat-Sen University, Guangzhou 510275, People's Republic of China
| | - C X Yue
- Liaoning Normal University, Dalian 116029, People's Republic of China
| | - A A Zafar
- University of the Punjab, Lahore-54590, Pakistan
| | - Y Zeng
- Hunan University, Changsha 410082, People's Republic of China
| | - B X Zhang
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - G Y Zhang
- Henan Normal University, Xinxiang 453007, People's Republic of China
| | - H Zhang
- University of Science and Technology of China, Hefei 230026, People's Republic of China
| | - H H Zhang
- Jilin University, Changchun 130012, People's Republic of China
| | - H H Zhang
- Sun Yat-Sen University, Guangzhou 510275, People's Republic of China
| | - H Y Zhang
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
| | - J J Zhang
- Shanxi Normal University, Linfen 041004, People's Republic of China
| | - J Q Zhang
- Nanjing Normal University, Nanjing 210023, People's Republic of China
| | - J W Zhang
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - J Y Zhang
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - J Z Zhang
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - Jianyu Zhang
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - Jiawei Zhang
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - Lei Zhang
- Nanjing University, Nanjing 210093, People's Republic of China
| | - S F Zhang
- Nanjing University, Nanjing 210093, People's Republic of China
| | - X D Zhang
- North China Electric Power University, Beijing 102206, People's Republic of China
| | - X Y Zhang
- Shandong University, Jinan 250100, People's Republic of China
| | - Y Zhang
- University of Oxford, Keble Road, Oxford OX13RH, United Kingdom
| | - Y T Zhang
- Zhengzhou University, Zhengzhou 450001, People's Republic of China
| | - Y H Zhang
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
| | - Yan Zhang
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Science and Technology of China, Hefei 230026, People's Republic of China
| | - Yao Zhang
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - Z Y Zhang
- Wuhan University, Wuhan 430072, People's Republic of China
| | - G Zhao
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - J Zhao
- Liaoning Normal University, Dalian 116029, People's Republic of China
| | - J Y Zhao
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - J Z Zhao
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
| | - Lei Zhao
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Science and Technology of China, Hefei 230026, People's Republic of China
| | - Ling Zhao
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - M G Zhao
- Nankai University, Tianjin 300071, People's Republic of China
| | - Q Zhao
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - S J Zhao
- Zhengzhou University, Zhengzhou 450001, People's Republic of China
| | - Y B Zhao
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
| | - Y X Zhao
- Institute of Modern Physics, Lanzhou 730000, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - Z G Zhao
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Science and Technology of China, Hefei 230026, People's Republic of China
| | - A Zhemchugov
- Joint Institute for Nuclear Research, 141980 Dubna, Moscow region, Russia
| | - B Zheng
- University of South China, Hengyang 421001, People's Republic of China
| | - J P Zheng
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
| | - Y H Zheng
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - B Zhong
- Nanjing Normal University, Nanjing 210023, People's Republic of China
| | - C Zhong
- University of South China, Hengyang 421001, People's Republic of China
| | - L P Zhou
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - Q Zhou
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - X Zhou
- Wuhan University, Wuhan 430072, People's Republic of China
| | - X K Zhou
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - X R Zhou
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Science and Technology of China, Hefei 230026, People's Republic of China
| | - A N Zhu
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - J Zhu
- Nankai University, Tianjin 300071, People's Republic of China
| | - K Zhu
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - K J Zhu
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - S H Zhu
- University of Science and Technology Liaoning, Anshan 114051, People's Republic of China
| | - W J Zhu
- Fudan University, Shanghai 200433, People's Republic of China
| | - W J Zhu
- Nankai University, Tianjin 300071, People's Republic of China
| | - Y C Zhu
- State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
- University of Science and Technology of China, Hefei 230026, People's Republic of China
| | - Z A Zhu
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - B S Zou
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| | - J H Zou
- Institute of High Energy Physics, Beijing 100049, People's Republic of China
| |
Collapse
|
29
|
Hong D, Lv D, Wu J, Li X, Zhao Q, Lu X, Li L. The Influence of Diagnosis Intervention Packet Policy Intervention on Medication Structure and Drug Cost of Elderly Hypertensive Inpatients in China: A Multicenter Interrupted Time-Series Analysis. Risk Manag Healthc Policy 2023; 16:1781-1790. [PMID: 37705992 PMCID: PMC10497050 DOI: 10.2147/rmhp.s418541] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/24/2023] [Accepted: 08/22/2023] [Indexed: 09/15/2023] Open
Abstract
Background DIP is a new medical insurance payment system developed in China which was implemented in Guangzhou in January 2018, but few studies have focused on its intervention effect on the drug burden of elderly hypertensive patients. Methods Nine medical institutions in Guangzhou, China, were selected, among which, daily full medical orders of elderly hypertensive inpatients from 2016 to 2020 were randomly collected. To assess the impact of DIP policy intervention on patient drug burden, we took the data after policy implementation in January 2018, as the intervention data, and applied a segmented regression model with interrupted time series to analyze the trend and changes in average daily drug costs per month and medication structure, stratified by age, sex, and inpatient department. Results A total of 34,276 elderly hypertensive patients' daily full medical orders were obtained. The immediate level change of drug costs after intervention was -23.884 RMB/month (P = 0.652), and the trend change was statistically significant (-15.642 RMB/month, P = 0.002). The relative cumulative effect at the end of the study was -78.860% (95% CI: -86.087% to -69.076%), and the intervention effect was more significant in surgical and male patients. The analysis of drug structure changes showed that after the implementation of the DIP policy intervention, the proportion of anti-infective drugs, anti-tumor drugs, and biological products all showed a significant downward trend (P < 0.05), while nutritional drugs showed a significant upward trend (P = 0.011), but no immediate horizontal change in slope was observed. Conclusion The typical practice in China showed that DIP policy intervention can improve the drug burden of elderly hypertensive hospitalized patients and has a stable long-term effect, and the intervention effect is not consistent across different clinical department and populations with different characteristics, and it would also cause changes in the medication structure.
Collapse
Affiliation(s)
- Dongsheng Hong
- Key Laboratory for Drug Evaluation and Clinical Research of Zhejiang Province, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, People’s Republic of China
- Department of Social Medicine of school of Public Health, Zhejiang University School of Medicine, Hangzhou, People’s Republic of China
| | - Duo Lv
- Key Laboratory for Drug Evaluation and Clinical Research of Zhejiang Province, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, People’s Republic of China
| | - Jiaying Wu
- Key Laboratory for Drug Evaluation and Clinical Research of Zhejiang Province, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, People’s Republic of China
| | - Xin Li
- Key Laboratory for Drug Evaluation and Clinical Research of Zhejiang Province, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, People’s Republic of China
| | - Qingwei Zhao
- Key Laboratory for Drug Evaluation and Clinical Research of Zhejiang Province, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, People’s Republic of China
| | - Xiaoyang Lu
- Key Laboratory for Drug Evaluation and Clinical Research of Zhejiang Province, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, People’s Republic of China
| | - Lu Li
- Department of Social Medicine of school of Public Health, Zhejiang University School of Medicine, Hangzhou, People’s Republic of China
| |
Collapse
|
30
|
Chen GC, Yang T, Zhao Q, Tang JM, Chuan H, Lin L, Gao HX. [Autologous umbilical cord mesenchymal stem cells for treatment of severe skin injury in an extremely low birth weight infant]. Zhonghua Er Ke Za Zhi 2023; 61:839-841. [PMID: 37650167 DOI: 10.3760/cma.j.cn112140-20230324-00206] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 09/01/2023]
Affiliation(s)
- G C Chen
- Department of Neonatology, Gansu Provincial Women and Child-care Hospital, Gansu Central Hospital, Gansu Provincial Pediatric Medical Center, Pediatric Clinical Medical Research Center of Gansu Province, Lanzhou 730050, China
| | - T Yang
- Department of Neonatology, Gansu Provincial Women and Child-care Hospital, Gansu Central Hospital, Gansu Provincial Pediatric Medical Center, Pediatric Clinical Medical Research Center of Gansu Province, Lanzhou 730050, China
| | - Q Zhao
- Department of Hematological Oncology, Gansu Provincial Women and Child-care Hospital, Gansu Central Hospital, Lanzhou 730050, China
| | - J M Tang
- Department of Neonatology, Gansu Provincial Women and Child-care Hospital, Gansu Central Hospital, Gansu Provincial Pediatric Medical Center, Pediatric Clinical Medical Research Center of Gansu Province, Lanzhou 730050, China
| | - H Chuan
- Department of Neonatology, Gansu Provincial Women and Child-care Hospital, Gansu Central Hospital, Gansu Provincial Pediatric Medical Center, Pediatric Clinical Medical Research Center of Gansu Province, Lanzhou 730050, China
| | - L Lin
- Department of Hematological Oncology, Gansu Provincial Women and Child-care Hospital, Gansu Central Hospital, Lanzhou 730050, China
| | - H X Gao
- Department of Neonatology, Gansu Provincial Women and Child-care Hospital, Gansu Central Hospital, Gansu Provincial Pediatric Medical Center, Pediatric Clinical Medical Research Center of Gansu Province, Lanzhou 730050, China
| |
Collapse
|
31
|
Gu BL, She Y, Pei GK, Du Y, Yang R, Ma LX, Zhao Q, Gao SG. Systematic analysis of prophages carried by Porphyromonas gingivalis. Infect Genet Evol 2023; 113:105489. [PMID: 37572952 DOI: 10.1016/j.meegid.2023.105489] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/05/2023] [Revised: 07/17/2023] [Accepted: 08/09/2023] [Indexed: 08/14/2023]
Abstract
To systematically investigate the prophages carrying in Porphyromonas gingivalis (P. gingivalis) strains, analyze potential antibiotic resistance genes (ARGs) and virulence genes in these prophages. We collected 90 whole genome sequences of P. gingivalis from NCBI and utilized the Prophage Hunter online software to predict prophages; Comprehensive antibiotic research database (CARD) and virulence factors database (VFDB) were adopted to analyze the ARGs and virulence factors (VFs) carried by the prophages. Sixty-nine prophages were identified among 24/90 P. gingivalis strains, including 17 active prophages (18.9%) and 52 ambiguous prophages (57.8%). The proportion of prophages carried by each P. gingivalis genome ranged from 0.5% to 6.7%. A total of 188 antibiotic resistance genes belonging to 25 phenotypes and 46 different families with six mechanisms of antibiotic resistance were identified in the 17 active prophages. Three active prophages encoded 4 virulence genes belonging to type III and type VI secretion systems. The potential hosts of these virulence genes included Escherichia coli, Shigella sonnei, Salmonella typhi, and Klebsiella pneumoniae. In conclusion, 26.7% P. gingivalis strains carry prophages, while the proportion of prophage genes in the P. gingivalis genome is relatively low. In addition, approximately 39.7% of the P. gingivalis prophage genes have ARGs identified, mainly against streptogramin, peptides, and aminoglycosides. Only a few prophages carry virulence genes. Prophages may play an important role in the acquisition, dissemination of antibiotic resistance genes, and pathogenicity evolution in P. gingivalis.
Collapse
Affiliation(s)
- B L Gu
- Henan Key Laboratory of Microbiome and Esophageal Cancer Prevention and Treatment, Henan Key Laboratory of Cancer Epigenetics, Cancer Hospital, The First Affiliated Hospital (College of Clinical Medicine) of Henan University of Science and Technology, Jianxi, Luoyang, Henan 471003, China
| | - Y She
- State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China
| | - G K Pei
- Henan Key Laboratory of Microbiome and Esophageal Cancer Prevention and Treatment, Henan Key Laboratory of Cancer Epigenetics, Cancer Hospital, The First Affiliated Hospital (College of Clinical Medicine) of Henan University of Science and Technology, Jianxi, Luoyang, Henan 471003, China
| | - Y Du
- Henan Key Laboratory of Microbiome and Esophageal Cancer Prevention and Treatment, Henan Key Laboratory of Cancer Epigenetics, Cancer Hospital, The First Affiliated Hospital (College of Clinical Medicine) of Henan University of Science and Technology, Jianxi, Luoyang, Henan 471003, China
| | - R Yang
- Henan Key Laboratory of Microbiome and Esophageal Cancer Prevention and Treatment, Henan Key Laboratory of Cancer Epigenetics, Cancer Hospital, The First Affiliated Hospital (College of Clinical Medicine) of Henan University of Science and Technology, Jianxi, Luoyang, Henan 471003, China
| | - L X Ma
- Henan Key Laboratory of Microbiome and Esophageal Cancer Prevention and Treatment, Henan Key Laboratory of Cancer Epigenetics, Cancer Hospital, The First Affiliated Hospital (College of Clinical Medicine) of Henan University of Science and Technology, Jianxi, Luoyang, Henan 471003, China
| | - Q Zhao
- State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.
| | - S G Gao
- Henan Key Laboratory of Microbiome and Esophageal Cancer Prevention and Treatment, Henan Key Laboratory of Cancer Epigenetics, Cancer Hospital, The First Affiliated Hospital (College of Clinical Medicine) of Henan University of Science and Technology, Jianxi, Luoyang, Henan 471003, China.
| |
Collapse
|
32
|
Fu Q, Zheng Y, Fang W, Zhao Q, Zhao P, Liu L, Zhai Y, Tong Z, Zhang H, Lin M, Zhu X, Wang H, Wang Y, Liu Z, Yuan D, Bao X, Gao W, Dai X, Li Z, Liang T. RUNX-3-expressing CAR T cells targeting glypican-3 in patients with heavily pretreated advanced hepatocellular carcinoma: a phase I trial. EClinicalMedicine 2023; 63:102175. [PMID: 37680942 PMCID: PMC10480529 DOI: 10.1016/j.eclinm.2023.102175] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/11/2023] [Revised: 08/04/2023] [Accepted: 08/08/2023] [Indexed: 09/09/2023] Open
Abstract
Background Glypican-3 (GPC3) is a well-characterized hepatocellular carcinoma (HCC)-associated antigen and a promising target for HCC treatment. CT017 CAR T cells were engineered to co-express CAR-GPC3 and runt-related transcription factor 3 (RUNX3), which triggers CD8+ T-cell infiltration into the cancer microenvironment. Methods This single-center, single-arm, open-label, phase I clinical study enrolled heavily pretreated patients with GPC3-positive HCC between August 2019 and December 2020 (NCT03980288). Patients were treated with CT017 CAR T cells at a dose of 250 × 106 cells. The primary objective was to assess the safety and tolerability of this first-in-human product. Findings Six patients received 7 infusions (one patient received 2 infusions) at the 250 × 106 cells dose. Three patients received CT017 monotherapy, and three patients received CT017-tyrosine kinase inhibitor (TKI) combination therapy at the first infusion. One patient received CT017-TKI combination therapy at the second infusion after CT017 monotherapy. All patients experienced cytokine release syndrome (CRS), with 50% (3/6) at Grade 2, 50% (3/6) at Grade 3, and all events resolved after treatment. No immune effector cell-associated neurotoxicity syndrome was observed. Dose escalation was not performed due to the investigator's decision regarding safety. Of six evaluable patients, one achieved partial response and two had stable disease for a 16.7% objective response rate, 50% disease control rate, 3.5-month median progression-free survival, 3.2-month median duration of disease control, and 7.9-month median overall survival (OS) with 7.87-month median follow-up. The longest OS was 18.2 months after CT017 infusion. Interpretation Current preliminary phase I data showed a manageable safety profile and promising antitumor activities of CT017 for patients with advanced HCC. These results need to be confirmed in a robust clinical trial. Funding This study was funded by CARsgen Therapeutics Co., Ltd.
Collapse
Affiliation(s)
- Qihan Fu
- Department of Medical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
- Key Laboratory of Cancer Prevention and Intervention, Ministry of Education, China
- The Key Laboratory of Pancreatic Diseases of Zhejiang Province, Hangzhou, China
| | - Yi Zheng
- Department of Medical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
| | - Weijia Fang
- Department of Medical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
- Key Laboratory of Cancer Prevention and Intervention, Ministry of Education, China
- The Key Laboratory of Pancreatic Diseases of Zhejiang Province, Hangzhou, China
| | - Qingwei Zhao
- Department of Clinical Pharmacy, The First Affiliated Hospital, Zhejiang University, Hangzhou, China
| | - Peng Zhao
- Department of Medical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
- Key Laboratory of Cancer Prevention and Intervention, Ministry of Education, China
| | - Lulu Liu
- Department of Medical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
| | - You Zhai
- Department of Clinical Pharmacy, The First Affiliated Hospital, Zhejiang University, Hangzhou, China
| | - Zhou Tong
- Department of Medical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
| | - Hangyu Zhang
- Department of Medical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
| | - Meihua Lin
- Department of Clinical Pharmacy, The First Affiliated Hospital, Zhejiang University, Hangzhou, China
| | - Xudong Zhu
- Department of Medical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
| | | | | | - Zhen Liu
- CARsgen Therapeutics Ltd., Shanghai, China
| | | | - Xuanwen Bao
- Department of Medical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
- Key Laboratory of Cancer Prevention and Intervention, Ministry of Education, China
| | - Wanwan Gao
- CARsgen Therapeutics Ltd., Shanghai, China
| | - Xiaomeng Dai
- Department of Medical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
- Key Laboratory of Cancer Prevention and Intervention, Ministry of Education, China
| | - Zonghai Li
- CARsgen Therapeutics Ltd., Shanghai, China
| | - Tingbo Liang
- The Key Laboratory of Pancreatic Diseases of Zhejiang Province, Hangzhou, China
- Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
- The Innovation Center for the Study of Pancreatic Diseases of Zhejiang Province, Hangzhou, China
- Zhejiang Clinical Research Center of Hepatobiliary and Pancreatic Diseases, Hangzhou, China
| |
Collapse
|
33
|
Guo HH, Hu YY, Tian Y, Yang PG, Ding PA, Wang D, Zhang ZD, Zhao XF, Liu Y, Li Y, Zhao Q. [Da Vinci robotic surgery for synchronous gastric and colorectal primary tumors: 8 cases]. Zhonghua Wei Chang Wai Ke Za Zhi 2023; 26:787-789. [PMID: 37574296 DOI: 10.3760/cma.j.cn441530-20221029-00440] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Subscribe] [Scholar Register] [Indexed: 08/15/2023]
|
34
|
Zou RY, Zhao Q, Tian YQ, Yan X, Qiu XH, Gao YJ, Liu Y, Huang M, Cao M, Dai JH, Cai HR. [Clinical characteristics and prognostic factors of patients with anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis associated interstitial lung disease]. Zhonghua Jie He He Hu Xi Za Zhi 2023; 46:781-790. [PMID: 37536988 DOI: 10.3760/cma.j.cn112147-20221017-00821] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Subscribe] [Scholar Register] [Indexed: 08/05/2023]
Abstract
Objective: To analyze the clinical characteristics and prognostic factors of patients with anti-melanoma differentiation-associated gene 5 (anti-MDA5)-positive dermatomyositis associated interstitial lung disease (DM-ILD). Methods: The patients with MDA5+DM-ILD who were admitted to Department of Respiratory Medicine, Nanjing Drum Tower Hospital from January 2017 to March 2021 were enrolled. The clinical data and survival information were analyzed retrospectively. Patients were divided into survival group or death group, and rapid progressive ILD (RP-ILD) group or non-rapid progressive ILD group, according to their survival status and clinical progression. Results: A total of 105 patients with anti-MDA5+DM-ILD (median age of onset 54 years) were enrolled, 58% being female (61 cases). The main sub-type of dermatomyositis was amyopathic dermatomyositis (n=74, 70%), followed by dermatomyositis (n=31, 30%). The main extrapulmonary manifestations were skin lesions (n=60, 57.1%), muscle manifestations(n=20, 19%) and arthralgia/arthritis (n=20, 19%). 15.4% of the patients had positive ANA (antibody titer≥1∶320), and 61.9% of the patients had anti-RO-52 kDa antibody. A total of 66 patients (62.8%) developed RP-ILD, and 58 patients (56.3%) died. Lower oxygenation index (OR=0.974, 95%CI:0.954-0.994, P=0.012) and no joint pain (OR=0.032, 95%CI: 0.002-0.663 P=0.026) were independent risk factors for RP-ILD. Cox regression analysis showed that RP-ILD (HR=3.194, 95%CI:1.025-9.954, P=0.045), older than 53 years (HR=3.450, 95%CI: 1.388-8.577, P=0.008), ferritin level more than 1 330.5 ng/ml (HR=3.032, 95%CI 1.208-7.610, P=0.018) and C-reactive protein (CRP) above 16.95 mg/L (HR=2.794, 95%CI:1.102-7.084, P=0.030) were independent predictors of mortality. Conclusions: The clinical manifestations of patients with anti-MDA5+DM-ILD presenting to the respiratory department were heterogeneous, with most being amyopathic dermatomyositis, and both the incidence of RP-ILD and the risk of death were high. Even in the absence of associated rash, joint, or muscle manifestations, anti-MDA5 antibody screening should be considered in patients with rapidly progressive ILD who were negative on baseline autoantibody screening but positive for anti-RO52kDa antibody.
Collapse
Affiliation(s)
- R Y Zou
- Department of Respiratory and Critical Care Medicine of Nanjing Drum Tower Hospital, Nanjing 210000, China
| | - Q Zhao
- Department of Respiratory and Critical Care Medicine of Nanjing Drum Tower Hospital, Nanjing 210000, China
| | - Y Q Tian
- Department of Respiratory and Critical Care Medicine of Nanjing Drum Tower Hospital, Nanjing 210000, China
| | - X Yan
- Department of Respiratory and Critical Care Medicine of Nanjing Drum Tower Hospital, Nanjing 210000, China
| | - X H Qiu
- Department of Respiratory and Critical Care Medicine of Nanjing Drum Tower Hospital, Nanjing 210000, China
| | - Y J Gao
- Department of Respiratory and Critical Care Medicine of Nanjing Drum Tower Hospital, Nanjing 210000, China
| | - Y Liu
- Department of Respiratory and Critical Care Medicine of Nanjing Drum Tower Hospital, Nanjing 210000, China
| | - M Huang
- Department of Respiratory and Critical Care Medicine of Nanjing Drum Tower Hospital, Nanjing 210000, China
| | - M Cao
- Department of Respiratory and Critical Care Medicine of Nanjing Drum Tower Hospital, Nanjing 210000, China
| | - J H Dai
- Department of Respiratory and Critical Care Medicine of Nanjing Drum Tower Hospital, Nanjing 210000, China
| | - H R Cai
- Department of Respiratory and Critical Care Medicine of Nanjing Drum Tower Hospital, Nanjing 210000, China
| |
Collapse
|
35
|
Hou SS, Wu YL, Luo W, Yin X, Sun ZX, Zhao Q, Zhao GM, Jiang YG, Wang N, Jiang QW. [Association between sedentary behavior and force expiratory volume in 1 second reduction in middle-aged and elderly adults in communities]. Zhonghua Liu Xing Bing Xue Za Zhi 2023; 44:1092-1098. [PMID: 37482712 DOI: 10.3760/cma.j.cn112338-20221111-00963] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Subscribe] [Scholar Register] [Indexed: 07/25/2023]
Abstract
Objective: To analyze the relationship between sedentary behavior and the force expiratory volume in 1 second (FEV1) reduction in middle-aged and elderly people in communities. Methods: The participants aged ≥40 years were randomly selected from a natural population cohort in Songjiang District, Shanghai, for pulmonary function tests and survey by using international physical activity questionnaire, a generalized additive model was used to analyze the association between sedentary behavior and FEV1 reduction in the study population and different sex-age subgroups. Results: A total of 3 121 study subjects aged ≥40 years were included. The prevalence of FEV1 reduction was 14.8%, which was higher in men than in women. There were 24.8% participants were completely sedentary. The prevalence of FEV1 reduction in women aged <60 years in complete sedentary group was 2.04 (95%CI: 1.11-3.72) times higher than that in non-complete sedentary group. In men aged <60 years, the prevalence of FEV1 reduction increased with daily sedentary time (OR=1.16, 95%CI: 1.04-1.29), and the prevalence of FEV1 reduction was also higher in those with sedentary time >5 hours/day than those with sedentary time ≤5 hours/day (OR=3.02, 95%CI: 1.28-7.16). The sensitivity analysis also found such associations. Conclusions: FEV1 reduction rate in age group <60 years was associated with sedentary behavior. Complete sedentary behavior or absence of moderate to vigorous physical activity played important roles in FEV1 reduction in women, while men were more likely to be affected by increased sedentary time, which had no association with physical activity. Reducing sedentary time to avoid complete sedentary behavior, along with increased physical activity, should be encouraged in middle-aged and elderly adults in communities to improve their pulmonary function.
Collapse
Affiliation(s)
- S S Hou
- Department of Epidemiology, School of Public Health, Fudan University, Shanghai 200032, China
| | - Y L Wu
- Songjiang District Center for Disease Control and Prevention, Shanghai 201620, China
| | - W Luo
- Songjiang District Center for Disease Control and Prevention, Shanghai 201620, China
| | - X Yin
- Department of Epidemiology, School of Public Health, Fudan University, Shanghai 200032, China
| | - Z X Sun
- Songjiang District Center for Disease Control and Prevention, Shanghai 201620, China
| | - Q Zhao
- Department of Epidemiology, School of Public Health, Fudan University, Shanghai 200032, China
| | - G M Zhao
- Department of Epidemiology, School of Public Health, Fudan University, Shanghai 200032, China
| | - Y G Jiang
- Songjiang District Center for Disease Control and Prevention, Shanghai 201620, China
| | - N Wang
- Department of Epidemiology, School of Public Health, Fudan University, Shanghai 200032, China
| | - Q W Jiang
- Department of Epidemiology, School of Public Health, Fudan University, Shanghai 200032, China
| |
Collapse
|
36
|
Wang YY, Zhao Q, Chen B, Wang N, Zhang TJ, Jiang YG, Wu YL, He N, Zhao GM, Liu X. [Association between metabolism-related chronic disease combination and prevalence of non-alcoholic fatty liver disease in community residents in Shanghai]. Zhonghua Liu Xing Bing Xue Za Zhi 2023; 44:1106-1113. [PMID: 37482714 DOI: 10.3760/cma.j.cn112338-20230106-00012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 07/25/2023]
Abstract
Objective: To explore the combination of metabolism-related chronic diseases associated with the prevalence of non-alcoholic fatty liver disease (NAFLD) in community residents in Shanghai. Methods: The baseline data of Shanghai Suburban Adult Cohort and Biobank were used to understand the prevalence of five metabolism-related chronic diseases, including obesity, hypertension, hyperlipidemia, gout and diabetes, based on questionnaire survey, physical examination and blood biochemical detection. NAFLD was diagnosed by B-ultrasound detection and questionnaire. Multivariable logistic regression model was used to analyze the association of 31 metabolism-related chronic diseases combinations with the prevalence of NAFLD. Results: The median age (Q1, Q3) of 65 477 subjects was 60 (51, 66) years, and men accounted for 40.6%. The overall prevalence of NAFLD was 38.2%, and the prevalence of HAFLD in patients without any of the five metabolism-related chronic diseases was 12.0%. The chronic disease combination with the strongest association with NAFLD was obesity + hypertension + hyperlipidemia + gout + diabetes in the total population (OR=37.94, 95%CI: 31.02-46.41), in women (OR=36.99, 95%CI: 28.78-47.54) and in age group ≥60 years (OR=36.19, 95%CI: 28.25-46.36). The chronic disease combination with the strongest association with NAFLD was obesity + hyperlipidemia + gout + diabetes in men (OR=50.70, 95%CI: 24.62-104.40) and in age group <60 years (OR=49.58, 95%CI: 24.22-101.47). Conclusions: The prevalence of NAFLD in community residents in Shanghai was high. Attention needs to be paid to health of obese people and weight loss should be promoted for them. Community health education should be strengthened for patients complicated with gout, diabetes, hyperlipidemia and hypertension and it is necessary to correct abnormal serum uric acid, blood sugar, blood lipids and blood pressure in a timely manner to reduce the risk of NAFLD.
Collapse
Affiliation(s)
- Y Y Wang
- Department of Epidemiology/Key Laboratory of Public Health Safety, Ministry of Education, School of Public Health, Fudan University, Shanghai 200032, China
| | - Q Zhao
- Department of Epidemiology/Key Laboratory of Public Health Safety, Ministry of Education, School of Public Health, Fudan University, Shanghai 200032, China
| | - B Chen
- Department of Epidemiology/Key Laboratory of Public Health Safety, Ministry of Education, School of Public Health, Fudan University, Shanghai 200032, China
| | - N Wang
- Department of Epidemiology/Key Laboratory of Public Health Safety, Ministry of Education, School of Public Health, Fudan University, Shanghai 200032, China
| | - T J Zhang
- Department of Epidemiology/Key Laboratory of Public Health Safety, Ministry of Education, School of Public Health, Fudan University, Shanghai 200032, China
| | - Y G Jiang
- Songjiang District Center for Disease Control and Prevention, Shanghai 201620, China
| | - Y L Wu
- Songjiang District Center for Disease Control and Prevention, Shanghai 201620, China
| | - N He
- Department of Epidemiology/Key Laboratory of Public Health Safety, Ministry of Education, School of Public Health, Fudan University, Shanghai 200032, China
| | - G M Zhao
- Department of Epidemiology/Key Laboratory of Public Health Safety, Ministry of Education, School of Public Health, Fudan University, Shanghai 200032, China
| | - X Liu
- Department of Epidemiology/Key Laboratory of Public Health Safety, Ministry of Education, School of Public Health, Fudan University, Shanghai 200032, China
| |
Collapse
|
37
|
Hong BA, Zhao Q, Ji YP, Cao YD, Yang Y, Zhang N. [The preliminary efficacy of "quadri-combination" therapy on the treatment of bladder cancer]. Zhonghua Yi Xue Za Zhi 2023; 103:1855-1859. [PMID: 37357192 DOI: 10.3760/cma.j.cn112137-20230314-00395] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Subscribe] [Scholar Register] [Indexed: 06/27/2023]
Abstract
To investigate the safety and efficacy of "quadri-combination" therapy including maximal transurethral resection of bladder tumor (mTURBT), combined with systemic chemotherapy and immunotherapy, concurrent radiotherapy, and immune maintenance therapy. The clinical data of 8 patients with bladder cancer who could not tolerate or refused radical cystectomy at the Department of Urology, Peking University Cancer Hospital from November 2019 to October 2021 were retrospectively analyzed. There were 5 males and 3 females with a mean age of 69 years. The Eastern Cooperative Oncology Group(ECOG) score was 0 in 6 cases and 1 in 2 cases. There were 5 cases of high-grade urothelial carcinoma (1 case of T3b; 2 cases were T2; 2 cases of T1 stage, with multiple tumors and repeated recurrence), 1 case of high-grade urothelial carcinoma with carcinoma in situ (T1/Tis stage), 1 case of high-grade urothelial carcinoma with squamous differentiation (T3b stage), and 1 case of high-grade urothelial carcinoma with glandular differentiation (T2). All patients underwent "quadri-combination" therapy.The patient's tolerance, success rate of bladder preservation and prognosis were evaluated.The median follow-up time was 22.5 (12-35) months. One patient with high-grade muscle-invasive bladder cancer (T2) received mTURBT, albumin-bound paclitaxel and durvalumab combined therapy for 3 cycles, concurrent radiotherapy, and immune maintenance therapy for 18 months, and the tumor recurrence was found. The pathology was high-grade urothelial carcinoma. Salvage radical cystectomy combined with pelvic lymph node dissection is recommended. The remaining 7 patients were regularly reexamined, and no recurrence or metastasis was found.The 2-year progression-free survival rate was 80%, and the success rate of bladder preservation was 87.5%(7/8). Treatment-related adverse reactions were resolved by symptomatic treatment, and patients' compliance and tolerance were acceptable.The "quadri-combination" bladder-preserving therapy is feasible and well tolerated, but further studies are needed.
Collapse
Affiliation(s)
- B A Hong
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Urology, Peking University Cancer Hospital & Institute, Beijing 100142, China
| | - Q Zhao
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Urology, Peking University Cancer Hospital & Institute, Beijing 100142, China
| | - Y P Ji
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Urology, Peking University Cancer Hospital & Institute, Beijing 100142, China
| | - Y D Cao
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Urology, Peking University Cancer Hospital & Institute, Beijing 100142, China
| | - Y Yang
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Urology, Peking University Cancer Hospital & Institute, Beijing 100142, China
| | - N Zhang
- Department of Urology, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China
| |
Collapse
|
38
|
Cheng HY, Ju JH, Zhao Q, Liu SZ, Zhang GL, Zhang T, Wang BY, Guo QW, Liu S. [Effects of free superficial peroneal artery perforator flap in repairing small and medium-sized thermal crush injury wounds in the hand]. Zhonghua Shao Shang Yu Chuang Mian Xiu Fu Za Zhi 2023; 39:546-551. [PMID: 37805770 DOI: 10.3760/cma.j.cn501225-20220623-00256] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 10/09/2023]
Abstract
Objective: To investigate the surgical methods and clinical effects of free superficial peroneal artery perforator flap in repairing small and medium-sized thermal crush injury wounds in the hand. Methods: A retrospective observational study was conducted. From August 2018 to December 2021, 12 patients (19 wounds) with small and medium-sized thermal crush injury in the hand who met the inclusion criteria were hospitalized in Suzhou Ruihua Orthopaedic Hospital, including 5 males and 7 females, aged from 30 to 54 years. The area of the wound was from 2.5 cm×2.0 cm to 14.0 cm×3.5 cm, and all the wounds were repaired by using free superficial peroneal artery perforator flaps from lower leg on one side (including single flap, multiple flaps, and multiple flaps with one pedicle resected from the same donor site). The area of the flap was from 3.5 cm×3.0 cm to 16.0 cm×4.0 cm. The wound in the donor site was sutured directly. The vascular crisis and survival of the flap were observed after operation. The texture, appearance, color, hyperpigmentation, sensation, and two-point discrimination of the flap repaired area were followed up, as well as the hyperplasia of scar and pain condition in the donor and recipient sites. At the last follow-up, the curative effect of flap repair was evaluated by the comprehensive evaluation scale, and the extension and flexion functions of the reserved digital joint were evaluated by the total active movement systematic evaluation method recommended by American Academy for Surgery of Hand. Results: One flap developed arterial crisis on the first day after operation but survived after timely exploration. The other 18 flaps survived successfully after operation. Follow-up of 4 to 24 months after operation showed good texture and appearance in the flap repaired area; the color of the flap repaired area was similar to that of the normal skin around the recipient site, without pigmentation; the protective sensation was restored in all cases, but there was no two-point discrimination; there was no obvious hypertrophic scarring or pain in the donor or recipient site. At the last follow-up, the curative effect of flap repair was evaluated with 3 flaps being excellent and 16 flaps being good; the extension and flexion functions of the reserved digital joint were also assessed, being excellent in 8 fingers, good in 9 fingers, and fair in 2 fingers. Conclusions: The blood supply of superficial peroneal artery perforator flap is sufficient and reliable, and multiple flaps of this type or multiple flaps with one pedicle can be resected from one donor site. The use of this flap to repair small and medium-sized thermal crush injury wounds in the hand results in minimal damage to the donor area, and good postoperative appearance and texture of the flap.
Collapse
Affiliation(s)
- H Y Cheng
- Department of Hand Surgery, Suzhou Ruihua Orthopaedic Hospital, Suzhou 215104, China
| | - J H Ju
- Department of Hand Surgery, Suzhou Ruihua Orthopaedic Hospital, Suzhou 215104, China
| | - Q Zhao
- Department of Hand Surgery, Suzhou Ruihua Orthopaedic Hospital, Suzhou 215104, China
| | - S Z Liu
- Department of Hand Surgery, Suzhou Ruihua Orthopaedic Hospital, Suzhou 215104, China
| | - G L Zhang
- Department of Hand Surgery, Suzhou Ruihua Orthopaedic Hospital, Suzhou 215104, China
| | - T Zhang
- Department of Hand Surgery, Suzhou Ruihua Orthopaedic Hospital, Suzhou 215104, China
| | - B Y Wang
- Department of Hand Surgery, Suzhou Ruihua Orthopaedic Hospital, Suzhou 215104, China
| | - Q W Guo
- Department of Hand Surgery, Suzhou Ruihua Orthopaedic Hospital, Suzhou 215104, China
| | - S Liu
- Department of Hand Surgery, Suzhou Ruihua Orthopaedic Hospital, Suzhou 215104, China
| |
Collapse
|
39
|
Wang ZY, Yang WL, Song YZ, Li DJ, Chen W, Zhao Q, Li YF, Cui R, Shen L, Liu Q, Wei CC, Zhai CB. [Comparison of corneal power assessment methods after small incision lenticule extraction]. Zhonghua Yan Ke Za Zhi 2023; 59:460-466. [PMID: 37264576 DOI: 10.3760/cma.j.cn112142-20220707-00330] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
Objective: To compare the accuracy of different corneal curvature parameters in assessing the corneal refractive status and tracking corneal power changes after small incision lenticule extraction (SMILE). Methods: This prospective cross-sectional study tracked and recorded total corneal curvature parameters measured by different instruments before and three months after SMILE for myopia. These parameters, including total keratometry (TK) from the IOLMaster 700, total corneal refractive power (TCRP) from the Pentacam AXL, real keratometry (RK) from the CASIA 2, and corrected parameters calculated using the Haigis, Shammas, and Maloney methods, were compared with data obtained using the clinical history method (CHM). Surgically induced changes in TK, TCRP, and RK were analyzed and compared with those in spherical equivalent on the corneal plane (ΔSEco). Results: The study included 40 eyes (40 participants). After SMILE, the difference was smallest between TK [(0.08±0.38) D] and CHM values (P>0.05). However, TCRP, RK, KHaigis, KShammas, and KMaloney were significantly different from CHM data (P<0.05). The width of the 95% limits of agreement of TK (1.49 D) was narrowest, followed by that of RK (1.57 D). Pearson analysis showed that each parameter had a good correlation with CHM data. The differences between the changes in TK, TCRP and RK caused by surgery and ΔSEco were (0.03±0.39) D, (0.17±0.43) D, and (-0.19±0.46) D, respectively. The width of the 95% limits of agreement of ΔTK (1.54 D) was narrowest, and the correlation coefficient of ΔTK (0.951) was highest. Conclusion: The parameter TK of the IOLMaster 700 can provide accurate and objective corneal power evaluation after SMILE.
Collapse
Affiliation(s)
- Z Y Wang
- Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing Institute of Ophthalmology, Beijing Key Laboratory of Ophthalmology & Visual Sciences, Beijing 100730, China
| | - W L Yang
- Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing Institute of Ophthalmology, Beijing Key Laboratory of Ophthalmology & Visual Sciences, Beijing 100730, China
| | - Y Z Song
- Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing Institute of Ophthalmology, Beijing Key Laboratory of Ophthalmology & Visual Sciences, Beijing 100730, China
| | - D J Li
- Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing Institute of Ophthalmology, Beijing Key Laboratory of Ophthalmology & Visual Sciences, Beijing 100730, China
| | - W Chen
- Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing Institute of Ophthalmology, Beijing Key Laboratory of Ophthalmology & Visual Sciences, Beijing 100730, China
| | - Q Zhao
- Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing Institute of Ophthalmology, Beijing Key Laboratory of Ophthalmology & Visual Sciences, Beijing 100730, China
| | - Y F Li
- Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing Institute of Ophthalmology, Beijing Key Laboratory of Ophthalmology & Visual Sciences, Beijing 100730, China
| | - R Cui
- Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing Institute of Ophthalmology, Beijing Key Laboratory of Ophthalmology & Visual Sciences, Beijing 100730, China
| | - L Shen
- Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing Institute of Ophthalmology, Beijing Key Laboratory of Ophthalmology & Visual Sciences, Beijing 100730, China
| | - Q Liu
- Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing Institute of Ophthalmology, Beijing Key Laboratory of Ophthalmology & Visual Sciences, Beijing 100730, China
| | - C C Wei
- Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing Institute of Ophthalmology, Beijing Key Laboratory of Ophthalmology & Visual Sciences, Beijing 100730, China
| | - C B Zhai
- Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing Institute of Ophthalmology, Beijing Key Laboratory of Ophthalmology & Visual Sciences, Beijing 100730, China
| |
Collapse
|
40
|
Guo W, Hu M, Xu N, Shangguan Y, Xia J, Hu W, Li X, Zhao Q, Xu K. The concentration of contezolid in cerebrospinal fluid and serum in a patient with tuberculous meningoencephalitis: A case report. Int J Antimicrob Agents 2023:106875. [PMID: 37276894 DOI: 10.1016/j.ijantimicag.2023.106875] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2022] [Revised: 03/08/2023] [Accepted: 05/31/2023] [Indexed: 06/07/2023]
Abstract
Central nervous system (CNS) tuberculosis (TB) is a devastating and often life-threatening disease caused by M. tuberculosis. Contezolid, a new oxazolidinone, has demonstrated potent antimycobacterial activity in both in vivo and in vitro studies, with lower toxicity than linezolid. However, the pharmacokinetic datav are still not available for contezolid in the CNS of patients with CNS TB. We report the steady-state concentrations in serum and CSF of a patient receiving contezolid as part of multi-drug treatment for tuberculous meningoencephalitis. At weeks 7 and 11 (7 hours post-dose) after initiation of contezolid therapy, the serum concentration of contezolid was 9.64mg/L and 9.36mg/L, respectively. In CSF, the observed concentration of contezolid was 0.54mg/L and 1.15mg/L. The CSF to serum concentration ratio was 0.056 and 0.123 at week 7 and week 11, respectively. The observed concentrations in CSF were above the minimum inhibitory concentration (MIC) of contezolid against M. tuberculosis and were close to the estimated serum unbound fraction of contezolid (10%), suggesting that the unbound contezolid penetrates well into CSF.
Collapse
Affiliation(s)
- Wanru Guo
- State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, No. 79 Qingchun Road, Hangzhou, 310003, Zhejiang, China
| | - Ming Hu
- State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, No. 79 Qingchun Road, Hangzhou, 310003, Zhejiang, China
| | - Nana Xu
- Zhejiang Provincial Key Laboratory for Drug Evaluation and Clinical Research, Department of Clinical Pharmacy, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, Zhejiang Province, China
| | - Yanwan Shangguan
- State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, No. 79 Qingchun Road, Hangzhou, 310003, Zhejiang, China
| | - Jiafeng Xia
- State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, No. 79 Qingchun Road, Hangzhou, 310003, Zhejiang, China
| | - Wenjuan Hu
- State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, No. 79 Qingchun Road, Hangzhou, 310003, Zhejiang, China
| | - Xiaomeng Li
- State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, No. 79 Qingchun Road, Hangzhou, 310003, Zhejiang, China
| | - Qingwei Zhao
- Zhejiang Provincial Key Laboratory for Drug Evaluation and Clinical Research, Department of Clinical Pharmacy, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, Zhejiang Province, China.
| | - Kaijin Xu
- State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, No. 79 Qingchun Road, Hangzhou, 310003, Zhejiang, China.
| |
Collapse
|
41
|
Huang Z, Xu K, Zhao L, Zheng LE, Xu N, Yan C, Hu X, Zhang Q, Liu J, Zhao Q, Xia Y. AND-Gated Nanosensor for Imaging of Glutathione and Apyrimidinic Endonuclease 1 in Cells, Animals, and Organoids. ACS Appl Mater Interfaces 2023. [PMID: 37245159 DOI: 10.1021/acsami.3c02236] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/29/2023]
Abstract
The development of a strategy for imaging of glutathione (GSH) and apurinic/apyrimidinic endonuclease 1 (APE1) in an organism remains challenging despite their significance in elaborating the correlated pathophysiological processes. Therefore, in this study, we propose a DNA-based AND-gated nanosensor for fluorescence imaging of the GSH as well as APE1 in living cells, animals, and organoids. The DNA probe is composed of a G-strand and A-strand. The disulfide bond in the G-strand is cleaved through a GSH redox reaction, and the hybridization stability between the G-strand and A-strand is decreased, leading to a conformational change of the A-strand. In the presence of APE1, the apurinic/apyrimidinic (AP) site in the A-strand is digested, producing a fluorescence signal for the correlated imaging of GSH and APE1. This nanosensor enables monitoring of the expression level change of GSH and APE1 in cells. Additionally, we illustrate the capability of this "dual-keys-and-locked" conceptual methodology in achieving specific tumor imaging when GSH and APE1 are present simultaneously (overexpressed GSH and APE1 in tumor cells) with improving tumor-to-normal tissue ratio in vivo. Furthermore, using this nanosensor, the GSH and APE1 also are visualized in organoids that recapitulate the phenotypic and functional traits of the original biological specimens. Overall, this study demonstrates the potential of our proposed biosensing technology in investigating the roles of various biological molecules involved in specific diseases.
Collapse
Affiliation(s)
- Zening Huang
- Department of Gastric Surgery, Fujian Medical University Union Hospital, Fuzhou 350001, China
| | - Kaixiang Xu
- Department of Gastric Surgery, Fujian Medical University Union Hospital, Fuzhou 350001, China
| | - Lijuan Zhao
- Department of Clinical Pharmacy, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China
- Zhejiang Provincial Key Laboratory for Drug Evaluation and Clinical Research, Hangzhou 310003, China
| | - Li-E Zheng
- Department of Gynecology, The First Affiliated Hospital of Fujian Medical University, Fuzhou 350004, China
| | - Nana Xu
- Department of Clinical Pharmacy, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China
- Zhejiang Provincial Key Laboratory for Drug Evaluation and Clinical Research, Hangzhou 310003, China
| | - Caixia Yan
- Department of Clinical Pharmacy, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China
- Zhejiang Provincial Key Laboratory for Drug Evaluation and Clinical Research, Hangzhou 310003, China
| | - Xingjiang Hu
- Department of Clinical Pharmacy, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China
- Zhejiang Provincial Key Laboratory for Drug Evaluation and Clinical Research, Hangzhou 310003, China
| | - Qiao Zhang
- Department of Clinical Pharmacy, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China
- Zhejiang Provincial Key Laboratory for Drug Evaluation and Clinical Research, Hangzhou 310003, China
| | - Jian Liu
- Department of Clinical Pharmacy, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China
- Zhejiang Provincial Key Laboratory for Drug Evaluation and Clinical Research, Hangzhou 310003, China
| | - Qingwei Zhao
- Department of Clinical Pharmacy, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China
- Zhejiang Provincial Key Laboratory for Drug Evaluation and Clinical Research, Hangzhou 310003, China
| | - Yaokun Xia
- Department of Clinical Pharmacy, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China
- Zhejiang Provincial Key Laboratory for Drug Evaluation and Clinical Research, Hangzhou 310003, China
| |
Collapse
|
42
|
Ye Z, Zhang Y, Chen J, Wang X, Hong Y, Zhao Q. First-line PD-1 inhibitors combination therapy for patients with advanced cholangiocarcinoma: A retrospective real-world study. Int Immunopharmacol 2023; 120:110344. [PMID: 37245298 DOI: 10.1016/j.intimp.2023.110344] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2023] [Revised: 05/02/2023] [Accepted: 05/12/2023] [Indexed: 05/30/2023]
Abstract
BACKGROUND Combination therapy with programmed cell death protein-1 (PD-1) inhibitors is currently the first-line treatment for advanced cholangiocarcinoma (CCA) in real-world settings. However, its effectiveness and safety are yet to be established. This study sought to assess the impact of this approach on the survival of this patient population. METHODS Our study included patients with advanced CCA who received first-line PD-1 inhibitors combination therapy at our hospital between September 2020 and April 2022 and were followed up until October 2022. Kaplan-Meier method was used to plot the survival curves. The Log-Rank method was used to compare differences in progression-free survival (PFS) and overall survival (OS) between groups. RESULTS A total of 54 patients with advanced CCA were enrolled. The objective response rate (ORR) and disease control rate (DCR) were 16.7% and 79.6%, respectively. The median PFS and OS were 6.6 (95% CI: 3.9-9.3) months and 13.9 (95% CI: 10.0-17.8) months, respectively. 88.9% of patients (n = 48) experienced at least one adverse event (AE) with grade ≥ 3 AEs occurring in 20 patients (37.0%). The most common grade ≥ 3 AEs were neutropenia (n = 6, 11.1%), anemia (n = 6, 11.1%), and thrombocytopenia (n = 6, 11.1%). 28 patients (51.9%) developed at least one immune-related adverse event (irAE). The most common irAEs reported were rash (n = 12, 22.2%), hypothyroidism (n = 11, 20.4%), and pruritus (n = 5, 9.3%). Four patients (7.4%) developed grade ≥ 3 irAEs, including rash (n = 1, 1.9%), pruritus (n = 1, 1.9%), colitis (n = 1, 1.9%), and pancreatitis (n = 1, 1.9%). In addition, patients with CEA ≤ 5 ng/ml prior to PD-1 inhibitors combination therapy experienced longer median PFS (9.0 months vs. 4.5 months, P = 0.016) and median OS (17.5 months vs. 11.3 months, P = 0.014) than those with CEA > 5 ng/ml. CONCLUSION Combination therapy with PD-1 inhibitors has demonstrated promising efficacy and manageable adverse events as a first-line treatment for advanced CCA in the real world.
Collapse
Affiliation(s)
- Ziqi Ye
- Department of Clinical Pharmacy, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China; Zhejiang Provincial Key Laboratory for Drug Evaluation and Clinical Research, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
| | - Yanfang Zhang
- Department of Clinical Pharmacy, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
| | - Jie Chen
- Department of Pharmacy, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
| | - Xiaoting Wang
- Department of Medical Oncology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
| | - Yun Hong
- Department of Clinical Pharmacy, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
| | - Qingwei Zhao
- Department of Clinical Pharmacy, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China; Zhejiang Provincial Key Laboratory for Drug Evaluation and Clinical Research, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
| |
Collapse
|
43
|
Liang YR, Yang YC, Yang BL, Zeng QX, Liu BY, Zhao Q, Luo Q, Zhao ZH, Yang T, Liu ZH, Xiong CM. [Evaluation effect of COMPERA 2.0 risk assessment model on prognosis of Chinese patients with pulmonary arterial hypertension]. Zhonghua Yi Xue Za Zhi 2023; 103:1410-1416. [PMID: 37150694 DOI: 10.3760/cma.j.cn112137-20221212-02625] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Subscribe] [Scholar Register] [Indexed: 05/09/2023]
Abstract
Objectives: To clarify the evaluation effect of COMPERA 2.0 risk assessment model on prognosis of pulmonary arterial hypertension (PAH) in China. Methods: Patients with newly diagnosed PAH admitted in Fuwai hospital between April 2019 and March 2022 were enrolled retrospectively and divided in low, intermediate-low, intermediate-high and high strata by scores of COMPERA 2.0 risk assessment model. All the patients were followed up by clinic or telephone. The primary endpoint was defined as a composite of all-cause mortality, exacerbated heart failure and aggravated symptoms. Kaplan-Meier analysis and log-rank trend test were used to determine the risk of endpoints among the 4 groups. Multivariate Cox proportional hazards regression were used to analyze the association between COMPERA 2.0 scores and prognosis in patients with PAH. Results: A total of 951 patients with PAH were enrolled in this study. The age [M (Q1, Q3)] of the patients was 35 (28, 47) years, of which 706 cases (74.2%) were females. A total of 328 cases (34.5%) were assigned in low strata, 264 cases (27.8%) in intermediate-low strata, 193 cases (20.3%) in intermediate-high strata, and 166 cases (17.5%) in high strata. During the duration [M (Q1, Q3)] of follow-up after discharge of 1.8 (1.0, 2.8) years, the primary endpoint was occurred in 12.8% (42/328), 21.2% (56/264), 28.5% (55/193) and 42.8% (71/166) of low, intermediate-low, intermediate-high and high strata, respectively. The rates of primary endpoint were significantly increased with strata rising (P<0.001). Multivariate Cox proportional hazards regression showed that COMPERA 2.0 risk scores were associated with the primary endpoints in PAH patients (HR=1.801, 95%CI: 1.254-2.588, P=0.001) after adjusting confounders. Conclusion: COMPERA 2.0 risk assessment model is a simple and effective tool for evaluating the prognosis of newly diagnosed PAH patients in China.
Collapse
Affiliation(s)
- Y R Liang
- Center of Pulmonary Vascular Disease, National Center for Cardiovascular Disease, Fuwai Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100037, China
| | - Y C Yang
- Center of Pulmonary Vascular Disease, National Center for Cardiovascular Disease, Fuwai Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100037, China
| | - B L Yang
- Center of Pulmonary Vascular Disease, National Center for Cardiovascular Disease, Fuwai Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100037, China
| | - Q X Zeng
- Center of Pulmonary Vascular Disease, National Center for Cardiovascular Disease, Fuwai Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100037, China
| | - B Y Liu
- Center of Pulmonary Vascular Disease, National Center for Cardiovascular Disease, Fuwai Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100037, China
| | - Q Zhao
- Center of Pulmonary Vascular Disease, National Center for Cardiovascular Disease, Fuwai Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100037, China
| | - Q Luo
- Center of Pulmonary Vascular Disease, National Center for Cardiovascular Disease, Fuwai Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100037, China
| | - Z H Zhao
- Center of Pulmonary Vascular Disease, National Center for Cardiovascular Disease, Fuwai Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100037, China
| | - T Yang
- Center of Pulmonary Vascular Disease, National Center for Cardiovascular Disease, Fuwai Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100037, China
| | - Z H Liu
- Center of Pulmonary Vascular Disease, National Center for Cardiovascular Disease, Fuwai Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100037, China
| | - C M Xiong
- Center of Pulmonary Vascular Disease, National Center for Cardiovascular Disease, Fuwai Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100037, China
| |
Collapse
|
44
|
Shen L, Zhai Y, Pan AX, Zhao Q, Zhou M, Liu J. Development of an integrated and comprehensive clinical trial process management system. BMC Med Inform Decis Mak 2023; 23:61. [PMID: 37024877 PMCID: PMC10078087 DOI: 10.1186/s12911-023-02158-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2021] [Accepted: 03/17/2023] [Indexed: 04/08/2023] Open
Abstract
BACKGROUND The process of initiating and completing clinical drug trials in hospital settings is highly complex, with numerous institutional, technical, and record-keeping barriers. In this study, we independently developed an integrated clinical trial management system (CTMS) designed to comprehensively optimize the process management of clinical trials. The CTMS includes system development methods, efficient integration with external business systems, terminology, and standardization protocols, as well as data security and privacy protection. METHODS The development process proceeded through four stages, including demand analysis and problem collection, system design, system development and testing, system trial operation, and training the whole hospital to operate the system. The integrated CTMS comprises three modules: project approval and review management, clinical trial operations management, and background management modules. These are divided into seven subsystems and 59 internal processes, realizing all the functions necessary to comprehensively perform the process management of clinical trials. Efficient data integration is realized through extract-transform-load, message queue, and remote procedure call services with external systems such as the hospital information system (HIS), laboratory information system (LIS), electronic medical record (EMR), and clinical data repository (CDR). Data security is ensured by adopting corresponding policies for data storage and data access. Privacy protection complies with laws and regulations and de-identifies sensitive patient information. RESULTS The integrated CTMS was successfully developed in September 2015 and updated to version 4.2.5 in March 2021. During this period, 1388 study projects were accepted, 43,051 electronic data stored, and 12,144 subjects recruited in the First Affiliated Hospital, Zhejiang University School of Medicine. CONCLUSION The developed integrated CTMS realizes the data management of the entire clinical trials process, providing basic conditions for the efficient, high-quality, and standardized operation of clinical trials.
Collapse
Affiliation(s)
- Liang Shen
- Department of Information Technology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, China
| | - You Zhai
- Research Center for Clinical Pharmacy, Department of Clinical Pharmacy, The First Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang Provincial Key Laboratory for Drug Evaluation and Clinical Research, Hangzhou, 310003, China
| | - AXiang Pan
- Department of Information Technology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, China
| | - Qingwei Zhao
- Research Center for Clinical Pharmacy, Department of Clinical Pharmacy, The First Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang Provincial Key Laboratory for Drug Evaluation and Clinical Research, Hangzhou, 310003, China
| | - Min Zhou
- Department of Information Technology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, China.
| | - Jian Liu
- Research Center for Clinical Pharmacy, Department of Clinical Pharmacy, The First Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang Provincial Key Laboratory for Drug Evaluation and Clinical Research, Hangzhou, 310003, China.
| |
Collapse
|
45
|
Gong TY, Guo L, Ye K, Zhao Q, Ye LY, Ma YN, Wang LF, Yang JY. [Phenotypic and genotypic characteristics of Escherichia coli causing bloodstream and abdominal co-infection]. Zhonghua Yi Xue Za Zhi 2023; 103:986-990. [PMID: 36990714 DOI: 10.3760/cma.j.cn112137-20220720-01579] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 03/31/2023]
Abstract
Objective: To analyze the phenotypic and genotypic characteristics of Escherichia coli causing bloodstream and abdominal co-infection (CoECO), and provide clues for empirical antibiotics treatment. Methods: The strains of Escherichia coli isolated from blood and abdominal samples in the Department of Laboratory Medicine of the First Medical Center of the PLA General Hospital from 2010 to 2020 were retrospectively analyzed. Mass spectrometer was used to identify all of the strains and the minimum inhibitory concentration (MIC) were detected by VITEK 2 Compact. All isolates were sequenced by 2×150 bp double terminal sequencing strategy on the HiSeq X Ten sequencer (Illumina). After the genome sequence was spliced, the single nucleotide polymorphism (SNP) analysis of the strain sequence was performed using kSNP3 software to clarify the homologous relationship between strains. If the strains isolated from two different parts had high homology, they were regarded as the same strain and the case was with CoECO infection. Meanwhile, the multilocus sequence type (MLST) was determined using PubMLST website and resistant genes were screened by CARD website. Results: A total of 70 cases of CoECO infection were screened, including 45 males and 25 females, and aged (59.2±16.3) years old. The 70 CoECO isolates belonged to 35 sequence types (STs). The most prevalent STs included ST38 (n=6), ST 405 (n=6), ST 1193 (n=6) and ST131 (n=5), and other ST types contained less than 5 strains. The homologous relationship among strains was relatively scattered, presenting a sporadic trend as a whole, and only a few strains had a small-scale outbreak. The CoECO isolates showed significantly resistance to ampicillin (91.4%, 64/70), ampicillin/sulbactam (74.3%, 5 2/70), ceftriaxone (72.9%, 51/70), ciprofloxacin (71.4%, 50/70) and levofloxacin (71.4%, 50/70), and high-sensitivity to piperacillin/tazobactam, carbapenems and amikacin. The most prevalent resistant gene was tet (A/B) (70%, 49/70), followed by blaTEM (58.6%, 41/70), sul1 (55.7%, 40/70), sul2 (54.3%, 38/70), blaCTX-M-14(25.7%, 18/70), blaCTX-M-15(17.1%, 13/70), blaCTX-M-55(15.7%, 11/70), blaCTX-M-64/65(5.7%, 4/70), blaCTX-M-27(4.3%, 3/70), mcr-1 (4.3%, 3/70), blaNDM-5(2.9%, 2/70). Conclusions: CoECO is distributed dispersedly and has no obvious advantage clone. No genotype with obvious advantages was found. Although the strain has a high resistance rate to some antibacterial drugs, the proportion of carrying resistant genes is low, and it has a high sensitivity to some first-line antibacterial drugs.
Collapse
Affiliation(s)
- T Y Gong
- Department of Laboratory Medicine, the First Medical Center of Chinese PLA General Hospital, Beijing 100853, China Graduate School, Medical School of Chinese PLA, Beijing 100039, China
| | - L Guo
- Department of Laboratory Medicine, the First Medical Center of Chinese PLA General Hospital, Beijing 100853, China
| | - K Ye
- Department of Laboratory Medicine, the First Medical Center of Chinese PLA General Hospital, Beijing 100853, China
| | - Q Zhao
- Department of Laboratory Medicine, the First Medical Center of Chinese PLA General Hospital, Beijing 100853, China
| | - L Y Ye
- Department of Laboratory Medicine, the First Medical Center of Chinese PLA General Hospital, Beijing 100853, China
| | - Y N Ma
- Department of Laboratory Medicine, the First Medical Center of Chinese PLA General Hospital, Beijing 100853, China
| | - L F Wang
- Department of Laboratory Medicine, the First Medical Center of Chinese PLA General Hospital, Beijing 100853, China
| | - J Y Yang
- Department of Laboratory Medicine, the First Medical Center of Chinese PLA General Hospital, Beijing 100853, China
| |
Collapse
|
46
|
Niu W, Rong X, Zhao Q, Liu X, Xu L, Li S, Li X. [Wine-processed Chuanxiong Rhizoma enhances efficacy of aumolertinib against EGFRmutant non-small cell lung cancer xenografts in nude mouse brain]. Nan Fang Yi Ke Da Xue Xue Bao 2023; 43:375-382. [PMID: 37087581 PMCID: PMC10122737 DOI: 10.12122/j.issn.1673-4254.2023.03.06] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 04/24/2023]
Abstract
OBJECTIVE To investigate the effect of wine-processed Chuanxiong Rhizoma (WCR) for enhancing the efficacy of aumolertinib against xenografts of epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) in the brain of nude mice. METHODS In a co-culture system of hCMEC/D3 and PC9 NSCLC cells, the effect of aqueous extract of WCR (2 mg/mL) combined with aumolertinib (10 and 20 μmol/L) on apoptosis of PC9 cells was investigated using flow cytometry. The effects of WCR extract (0.5, 1, and 2 mg/mL) on transmembrane transport of 8 μmol/L aumolertinib was examined in ABCB1-MDCK monolayer cells. Western blotting was used to detect the expressions of the tight junction proteins related with blood- brain barrier integrity. A nude mouse model bearing NSCLC xenograft in the brain was established to observe the inhibitory effect of WCR (1 mg/g) combined with aumolertinib (10 mg/kg) on tumor growth. RESULTS Compared with aumolertinib (20 μmol/L) alone, WCR extract (2 mg/mL) combined with aumolertinib significantly increased the apoptosis rate of PC9 cells by 21% (P < 0.01). The combined treatment with WCR (0.5, 1, 2 mg/mL) obviously increased apical-basolateral transport of aumolertinib in ABCB1-MDCK monolayer cells (P < 0.05) and significantly lowered the expression levels of zonula occludens-1, claudin-5 and P-glycoprotein (P < 0.05). In the tumor-bearing mice, compared with aumolertinib alone, the combined treatment with WCR and aumolertinib produced stronger inhibitory effect on tumor growth, improved weight loss, and prolonged the survival time of the nude mice (P < 0.05). Pathological examination showed that the combined treatment obviously increased the apoptosis rate of the tumor cells and alleviated neural injuries in the brain. Immunohistochemistry revealed that WCR treatment significantly reduced the expressions of ZO-1 and claudin-5 in the brain of the mice. CONCLUSION WCR combined with aumolertinib shows stronger inhibitory effects against tumor xenografts of EGFR-mutant NSCLC possibly due to the effect of WCR in facilitating the transmembrane transport of aumolertinib by downregulating ZO-1, claudin-5 and P-glycoprotein expression.
Collapse
Affiliation(s)
- W Niu
- School of Pharmacy, Bengbu Medical College, Bengbu 233030, China
| | - X Rong
- School of Pharmacy, Bengbu Medical College, Bengbu 233030, China
| | - Q Zhao
- School of Pharmacy, Bengbu Medical College, Bengbu 233030, China
| | - X Liu
- School of Pharmacy, Bengbu Medical College, Bengbu 233030, China
| | - L Xu
- School of Pharmacy, Bengbu Medical College, Bengbu 233030, China
| | - S Li
- School of Pharmacy, Bengbu Medical College, Bengbu 233030, China
| | - X Li
- School of Pharmacy, Bengbu Medical College, Bengbu 233030, China
- Anhui Provincial Key Laboratory of New Technology of Chinese Herbal Pieces Manufacturing, Bozhou 236800, China
- Postdoctoral Workstation of Anhui Xiehecheng Pharmaceutical Yinpian Co Ltd, Bozhou 236800, China
| |
Collapse
|
47
|
Li YF, Yang WL, Wei WB, Yang LL, Xu XL, Zhang X, Wang Q, Wang S, Li DJ, Wang ZY, Chen W, Zhao Q, Cui R, Shen L, Liu Q. [Ultrasonographic features of retinal pigment epithelial adenoma]. Zhonghua Yan Ke Za Zhi 2023; 59:181-186. [PMID: 36860104 DOI: 10.3760/cma.j.cn112142-20220803-00382] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 03/03/2023]
Abstract
Objective: To investigate the ultrasonographic features of retinal pigment epithelium (RPE) adenoma. Methods: It was a retrospective case series study. The clinical clata of 15 patients (15 eyes) with pathologically confirmed RPE adenoma after local resection of intraocular tumor was collected at Beijing Tongren Hospital, Capital Medical University from November 2013 to October 2019. The general conditions of the patients and the location, size, shape, internal echo features of the lesions in the ocular ultrasound sonogram were analyzed, and the blood flow in the lesions was checked by color Doppler flow imaging (CDFI). Results: Of all the patients included in the study, 7 were male and 8 were female. Their age ranged from 25 to 58 years, with a mean age of (45.7±10.2) years. The most common symptom was vision loss or blurred vision (11 cases). Other symptoms included dark shadows or obscuration in front of the eyes (3 cases) and no symptoms (1 case). A history of previous ocular trauma was present in one case, and the rest of the patients had no history of ocular trauma.The location of tumor growth is scattered. The ultrasonographic features were as follows: the average maximum basal diameter was (8.07±2.75) mm and the average height was (4.02±1.81) mm; the ultrasonographic features mostly demonstrated abruptly elevated dome-shaped echo (6 cases); the lesion edge was not smooth, the internal echo was medium or low, and there could be hollow features (2 cases), with no choroidal depression; and the blood flow signal could be seen in the CDFI lesion, which could lead to retinal detachment and vitreous opacification. Conclusion: The ultrasound imaging features of RPE adenomas mostly demonstrate abruptly elevated dome-shaped echo, unsmooth lesion edge, with no choroidal depression, which may provide valuable evidence for clinical diagnosis and differentiation.
Collapse
Affiliation(s)
- Y F Li
- Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing Institute of Ophthalmology, Beijing Key Laboratory of Ophthalmology & Visual Sciences, Beijing 100730, China
| | - W L Yang
- Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing Institute of Ophthalmology, Beijing Key Laboratory of Ophthalmology & Visual Sciences, Beijing 100730, China
| | - W B Wei
- Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing Institute of Ophthalmology, Beijing Key Laboratory of Ophthalmology & Visual Sciences, Beijing 100730, China
| | - L L Yang
- Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing Institute of Ophthalmology, Beijing Key Laboratory of Ophthalmology & Visual Sciences, Beijing 100730, China
| | - X L Xu
- Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing Institute of Ophthalmology, Beijing Key Laboratory of Ophthalmology & Visual Sciences, Beijing 100730, China
| | - X Zhang
- Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing Institute of Ophthalmology, Beijing Key Laboratory of Ophthalmology & Visual Sciences, Beijing 100730, China
| | - Q Wang
- Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing Institute of Ophthalmology, Beijing Key Laboratory of Ophthalmology & Visual Sciences, Beijing 100730, China
| | - S Wang
- Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing Institute of Ophthalmology, Beijing Key Laboratory of Ophthalmology & Visual Sciences, Beijing 100730, China
| | - D J Li
- Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing Institute of Ophthalmology, Beijing Key Laboratory of Ophthalmology & Visual Sciences, Beijing 100730, China
| | - Z Y Wang
- Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing Institute of Ophthalmology, Beijing Key Laboratory of Ophthalmology & Visual Sciences, Beijing 100730, China
| | - W Chen
- Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing Institute of Ophthalmology, Beijing Key Laboratory of Ophthalmology & Visual Sciences, Beijing 100730, China
| | - Q Zhao
- Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing Institute of Ophthalmology, Beijing Key Laboratory of Ophthalmology & Visual Sciences, Beijing 100730, China
| | - R Cui
- Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing Institute of Ophthalmology, Beijing Key Laboratory of Ophthalmology & Visual Sciences, Beijing 100730, China
| | - L Shen
- Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing Institute of Ophthalmology, Beijing Key Laboratory of Ophthalmology & Visual Sciences, Beijing 100730, China
| | - Q Liu
- Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing Institute of Ophthalmology, Beijing Key Laboratory of Ophthalmology & Visual Sciences, Beijing 100730, China
| |
Collapse
|
48
|
Zhao Q, Pan S, Zhang L, Zhang Y, Shahsavari A, Lotey P, Baetge CL, Deveau MA, Gregory CA, Kapler GM, Liu F. A Salivary Gland Resident Macrophage Subset Regulating Radiation Responses. J Dent Res 2023; 102:536-545. [PMID: 36883649 PMCID: PMC10150438 DOI: 10.1177/00220345221150005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/09/2023] Open
Abstract
Radiotherapy of head and neck cancers frequently leads to irreversible hypofunction of salivary glands, which severely compromises the quality of life and is extremely difficult to treat. We found recently that salivary gland resident macrophages are sensitive to radiation and interact with epithelial progenitors and endothelial cells through homeostatic paracrine factors. Heterogeneous subpopulations of resident macrophages are present in other organs with distinct functions, whereas subpopulations of salivary gland resident macrophages with distinct functions or transcriptional profiles have not been reported yet. Using single-cell RNA sequencing, we found that mouse submandibular glands (SMGs) contain 2 distinct self-renewing resident macrophage subsets, an MHC-IIhi subset present in many other organs and an uncommon Csf2r+ subset. The main source of Csf2 in SMGs are innate lymphoid cells (ILCs) that rely on IL15 for maintenance, while the main source of IL15 protein is Csf2r+ resident macrophages, indicating a homeostatic paracrine interaction between these cells. Csf2r+ resident macrophages are the major source of hepatocyte growth factor (Hgf) that regulates homeostasis of SMG epithelial progenitors. Meanwhile, Csf2r+ resident macrophages are responsive to Hedgehog signaling that can rescue salivary function impaired by radiation. Consistently, irradiation persistently decreased numbers of ILCs and levels of IL15 and Csf2 in SMGs, which were all recovered by transient activation of Hedgehog signaling after radiation. Csf2r+ resident macrophages and MHC-IIhi resident macrophages share transcriptome profiles of perivascular macrophages and macrophages associated with nerves and/or epithelial cells in other organs, respectively, and such niche preferences were supported by lineage tracing and immunofluorescent staining. These findings reveal an uncommon resident macrophage subset that regulates the homeostasis of the salivary gland and is promising as the target to restore salivary gland function impaired by radiation.
Collapse
Affiliation(s)
- Q Zhao
- Cell Biology and Genetics Department, College of Medicine, Texas A&M University Health Science Center, College Station, TX, USA
| | - S Pan
- Cell Biology and Genetics Department, College of Medicine, Texas A&M University Health Science Center, College Station, TX, USA
| | - L Zhang
- Cell Biology and Genetics Department, College of Medicine, Texas A&M University Health Science Center, College Station, TX, USA
| | - Y Zhang
- Cell Biology and Genetics Department, College of Medicine, Texas A&M University Health Science Center, College Station, TX, USA
| | - A Shahsavari
- Cell Biology and Genetics Department, College of Medicine, Texas A&M University Health Science Center, College Station, TX, USA
| | - P Lotey
- Cell Biology and Genetics Department, College of Medicine, Texas A&M University Health Science Center, College Station, TX, USA
| | - C L Baetge
- Department of Small Animal Clinical Sciences, College of Veterinary Medicine & Biomedical Sciences, Texas A&M University, College Station, TX, USA
| | - M A Deveau
- Department of Small Animal Clinical Sciences, College of Veterinary Medicine & Biomedical Sciences, Texas A&M University, College Station, TX, USA
| | - C A Gregory
- Cell Biology and Genetics Department, College of Medicine, Texas A&M University Health Science Center, College Station, TX, USA
| | - G M Kapler
- Cell Biology and Genetics Department, College of Medicine, Texas A&M University Health Science Center, College Station, TX, USA
| | - F Liu
- Cell Biology and Genetics Department, College of Medicine, Texas A&M University Health Science Center, College Station, TX, USA
| |
Collapse
|
49
|
Zhao Q, Sun X, Liu K, Peng Y, Jin D, Shen W, Wang R. Correlation between capsule endoscopy classification and CT lymphangiography of primary intestinal lymphangiectasia. Clin Radiol 2023; 78:219-226. [PMID: 36509551 DOI: 10.1016/j.crad.2022.10.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2022] [Revised: 09/21/2022] [Accepted: 10/05/2022] [Indexed: 12/13/2022]
Abstract
AIM To investigate the correlation between capsule endoscopy (CE) classification of primary intestinal lymphangiectasia (PIL) and computed tomography (CT) lymphangiography (CTL). MATERIALS AND METHODS A total of 52 patients with diagnosed PIL were enrolled. All patients were examined using CTL and small intestinal CE before surgery. CE assessments included the morphology, scope, colour, and size of lesions. CTL assessments included intestinal wall, lymphatic vessel dilatation, lymph fluid reflux, and lymphatic fistula. Patients were divided into three groups according to type diagnosed by CE, and the CTL characteristics were analysed among the groups. RESULTS CE showed 15 patients with type I, 27 with II, and 10 with type III. Intestinal wall thickening was observed in 15 type I, 21 type II, and seven type III. Pericardial effusion was observed in only three type I patients; the difference among types was statistically significant (p=0.02). Abnormal contrast agent distribution in the intestinal wall and mesentery was observed in 15 type II patients, and the difference was significantly greater than that of types I and III (p=0.02). Abnormal contrast agent distribution in the abdominal cavity was observed in 12 type II, and the difference was statistically significant (p=0.03). CONCLUSION The CE PIL classification reflects the extent and scope of intestinal mucosa lesions; CTL more systematically demonstrates abnormal lymphatic vessels or reflux, and its manifestations of PIL are related to the CE classification. The combination of CTL with CE is useful for accurately evaluating PIL, and provides guidance for preoperative assessment and treatment management of PIL patients.
Collapse
Affiliation(s)
- Q Zhao
- Department of Radiology, Peking University Ninth School of Clinical Medicine, Beijing Shijitan Hospital, Capital Medical University, Beijing, China
| | - X Sun
- Department of Radiology, Peking University Ninth School of Clinical Medicine, Beijing Shijitan Hospital, Capital Medical University, Beijing, China
| | - K Liu
- Department of Gastroenterology, Peking University Ninth School of Clinical Medicine, Beijing Shijitan Hospital, Capital Medical University, Beijing, China
| | - Y Peng
- Beijing Jiaotong University, China
| | - D Jin
- Peking University Third Hospital, China
| | - W Shen
- Department of Lymph Surgery, Peking University Ninth School of Clinical Medicine, Beijing Shijitan Hospital, Capital Medical University, Beijing, China
| | - R Wang
- Department of Radiology, Peking University Ninth School of Clinical Medicine, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.
| |
Collapse
|
50
|
Huang Y, Jin F, Huang Y, Zhao Q, Wu Q, MA K. WCN23-0335 Validation of deep learning integration technology for assisting clinical diagnosis of renal pathologists. Kidney Int Rep 2023. [DOI: 10.1016/j.ekir.2023.02.256] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/22/2023] Open
|